|
<html> |
|
<title> - EXAMINING MEDICAID AND CHIP'S FEDERAL MEDICAL ASSISTANCE PERCENTAGE</title> |
|
<body><pre> |
|
[House Hearing, 114 Congress] |
|
[From the U.S. Government Publishing Office] |
|
|
|
|
|
|
|
|
|
|
|
EXAMINING MEDICAID AND CHIP'S FEDERAL MEDICAL ASSISTANCE PERCENTAGE |
|
|
|
======================================================================= |
|
|
|
HEARING |
|
|
|
BEFORE THE |
|
|
|
SUBCOMMITTEE ON HEALTH |
|
|
|
OF THE |
|
|
|
COMMITTEE ON ENERGY AND COMMERCE |
|
HOUSE OF REPRESENTATIVES |
|
|
|
ONE HUNDRED FOURTEENTH CONGRESS |
|
|
|
SECOND SESSION |
|
|
|
__________ |
|
|
|
FEBRUARY 10, 2016 |
|
|
|
__________ |
|
|
|
Serial No. 114-115 |
|
|
|
|
|
|
|
|
|
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Printed for the use of the Committee on Energy and Commerce |
|
|
|
energycommerce.house.gov |
|
______ |
|
|
|
U.S. GOVERNMENT PUBLISHING OFFICE |
|
|
|
20-030 WASHINGTON : 2017 |
|
----------------------------------------------------------------------- |
|
For sale by the Superintendent of Documents, U.S. Government Publishing |
|
Office Internet: bookstore.gpo.gov Phone: toll free (866) 512-1800; |
|
DC area (202) 512-1800 Fax: (202) 512-2104 Mail: Stop IDCC, |
|
Washington, DC 20402-0001 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COMMITTEE ON ENERGY AND COMMERCE |
|
|
|
FRED UPTON, Michigan |
|
Chairman |
|
JOE BARTON, Texas FRANK PALLONE, Jr., New Jersey |
|
Chairman Emeritus Ranking Member |
|
ED WHITFIELD, Kentucky BOBBY L. RUSH, Illinois |
|
JOHN SHIMKUS, Illinois ANNA G. ESHOO, California |
|
JOSEPH R. PITTS, Pennsylvania ELIOT L. ENGEL, New York |
|
GREG WALDEN, Oregon GENE GREEN, Texas |
|
TIM MURPHY, Pennsylvania DIANA DeGETTE, Colorado |
|
MICHAEL C. BURGESS, Texas LOIS CAPPS, California |
|
MARSHA BLACKBURN, Tennessee MICHAEL F. DOYLE, Pennsylvania |
|
Vice Chairman JANICE D. SCHAKOWSKY, Illinois |
|
STEVE SCALISE, Louisiana G.K. BUTTERFIELD, North Carolina |
|
ROBERT E. LATTA, Ohio DORIS O. MATSUI, California |
|
CATHY McMORRIS RODGERS, Washington KATHY CASTOR, Florida |
|
GREGG HARPER, Mississippi JOHN P. SARBANES, Maryland |
|
LEONARD LANCE, New Jersey JERRY McNERNEY, California |
|
BRETT GUTHRIE, Kentucky PETER WELCH, Vermont |
|
PETE OLSON, Texas BEN RAY LUJAN, New Mexico |
|
DAVID B. McKINLEY, West Virginia PAUL TONKO, New York |
|
MIKE POMPEO, Kansas JOHN A. YARMUTH, Kentucky |
|
ADAM KINZINGER, Illinois YVETTE D. CLARKE, New York |
|
H. MORGAN GRIFFITH, Virginia DAVID LOEBSACK, Iowa |
|
GUS M. BILIRAKIS, Florida KURT SCHRADER, Oregon |
|
BILL JOHNSON, Ohio JOSEPH P. KENNEDY, III, |
|
BILLY LONG, Missouri Massachusetts |
|
RENEE L. ELLMERS, North Carolina TONY CARDENAS, California |
|
LARRY BUCSHON, Indiana |
|
BILL FLORES, Texas |
|
SUSAN W. BROOKS, Indiana |
|
MARKWAYNE MULLIN, Oklahoma |
|
RICHARD HUDSON, North Carolina |
|
CHRIS COLLINS, New York |
|
KEVIN CRAMER, North Dakota |
|
Subcommittee on Health |
|
|
|
JOSEPH R. PITTS, Pennsylvania |
|
Chairman |
|
BRETT GUTHRIE, Kentucky GENE GREEN, Texas |
|
Vice Chairman Ranking Member |
|
ED WHITFIELD, Kentucky ELIOT L. ENGEL, New York |
|
JOHN SHIMKUS, Illinois LOIS CAPPS, California |
|
TIM MURPHY, Pennsylvania JANICE D. SCHAKOWSKY, Illinois |
|
MICHAEL C. BURGESS, Texas G.K. BUTTERFIELD, North Carolina |
|
MARSHA BLACKBURN, Tennessee KATHY CASTOR, Florida |
|
CATHY McMORRIS RODGERS, Washington JOHN P. SARBANES, Maryland |
|
LEONARD LANCE, New Jersey DORIS O. MATSUI, California |
|
H. MORGAN GRIFFITH, Virginia BEN RAY LUJAN, New Mexico |
|
GUS M. BILIRAKIS, Florida KURT SCHRADER, Oregon |
|
BILLY LONG, Missouri JOSEPH P. KENNEDY, III, |
|
RENEE L. ELLMERS, North Carolina Massachusetts |
|
LARRY BUCSHON, Indiana TONY CARDENAS, California |
|
SUSAN W. BROOKS, Indiana FRANK PALLONE, Jr., New Jersey (ex |
|
CHRIS COLLINS, New York officio) |
|
JOE BARTON, Texas |
|
FRED UPTON, Michigan (ex officio) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
C O N T E N T S |
|
|
|
---------- |
|
Page |
|
Hon. Joseph R. Pitts, a Representative in Congress from the |
|
Commonwealth of Pennsylvania, opening statement................ 1 |
|
Prepared statement........................................... 3 |
|
Hon. Marsha Blackburn, a Representative in Congress from the |
|
State of Tennessee, opening statement.......................... 5 |
|
Hon. Frank Pallone, Jr., a Representative in Congress from the |
|
State of New Jersey, opening statement......................... 6 |
|
|
|
Witnesses |
|
|
|
Alison Mitchell, Analyst in Health Care Financing, Congressional |
|
Research Service............................................... 8 |
|
Prepared statement........................................... 10 |
|
Anne Schwartz, Ph.D., Executive Director, Medicaid and CHIP |
|
Payment and Access Commission.................................. 13 |
|
Prepared statement........................................... 15 |
|
Answers to submitted questions............................... 106 |
|
Carolyn Yocom, Director Of Health Care, Government Accountability |
|
Office......................................................... 33 |
|
Prepared statement........................................... 35 |
|
Answers to submitted questions............................... 108 |
|
John Hagg, Director of the Medicaid Audits, Office of Inspector |
|
General, U.S. Department of Health and Human Services.......... 49 |
|
Prepared statement........................................... 51 |
|
Answers to submitted questions............................... 113 |
|
|
|
Submitted Material |
|
|
|
Chart entitled, ``FY2014 Total Spending $3.5 Trillion, submitted |
|
by Mr. Shimkus................................................. 70 |
|
Statement of the Illinois Health and Hospital Association, |
|
submitted by Ms. Schakowsky.................................... 90 |
|
Statement of the American Academy of Pediatrics, submitted by Mr. |
|
Pitts.......................................................... 91 |
|
|
|
|
|
EXAMINING MEDICAID AND CHIP'S FEDERAL MEDICAL ASSISTANCE PERCENTAGE |
|
|
|
---------- |
|
|
|
|
|
WEDNESDAY, FEBRUARY 10, 2016 |
|
|
|
House of Representatives, |
|
Subcommittee on Health, |
|
Committee on Energy and Commerce, |
|
Washington, DC. |
|
The subcommittee met, pursuant to call, at 10:00 a.m., in |
|
room 2123 Rayburn House Office Building, Hon. Joe Pitts |
|
(chairman of the subcommittee) presiding. |
|
Members present: Representatives Pitts, Guthrie, Shimkus, |
|
Murphy, Blackburn, Lance, Griffith, Bilirakis, Long, Ellmers, |
|
Bucshon, Brooks, Collins, Engel, Capps, Schakowsky, Castor, |
|
Sarbanes, Matsui, Luja AE1n, Schrader, Kennedy, Ca AE1rdenas, |
|
and Pallone (ex officio). |
|
Staff present: Rebecca Card, Assistant Press Secretary; |
|
Paul Edattel, Chief Counsel, Health; Tim Pataki, Member |
|
Services Director; Graham Pittman, Legislative Clerk, Health; |
|
Michelle Rosenberg, GAO Detailee, Health; Chris Santini, Policy |
|
Coordinator, Oversight and Investigations; Chris Sarley, Policy |
|
Coordinator, Environment and the Economy; Heidi Stirrup, Policy |
|
Coordinator, Health; Sophie Trainor, Policy Advisor, Health; |
|
Josh Trent, Deputy Chief Counsel, Health; Christine Brennan, |
|
Minority Press Secretary; Jeff Carroll, Minority Staff |
|
Director; Tiffany Guarascio, Minority Deputy Staff Director and |
|
Chief Health Advisor; Rachel Pryor, Minority Health Policy |
|
Advisor; Samantha Satchell, Minority Policy Analyst; and Andrew |
|
Souvall, Minority Director of Communications, Outreach, and |
|
Member Services. |
|
|
|
OPENING STATEMENT OF HON. JOSEPH R. PITTS, A REPRESENTATIVE IN |
|
CONGRESS FROM THE COMMONWEALTH OF PENNSYLVANIA |
|
|
|
Mr. Pitts. The subcommittee will come to order. The |
|
chairman recognizes himself for an opening statement. |
|
Today's hearing will provide an opportunity for members to |
|
discuss the Federal Medical Assistance Percentage or FMAP rate. |
|
The FMAP is the Federal statutory financing formula that is the |
|
basis for determining the federal government's financial share |
|
of most Medicaid and Children's Health Insurance Program |
|
expenditures, CHIP. |
|
While exploring the FMAP may seem like a dense topic to |
|
some, today's hearing allows members to look under the cabinet |
|
to examine Medicaid's plumbing, how money flows throughout the |
|
system. It is important for members to understand how the FMAP |
|
works, because it impacts how an estimated $545 billion in |
|
program expenditures will be spent this year. |
|
Federal law specifies the formula for calculating Federal |
|
Medical Assistance Percentages and requires the Secretary of |
|
Health and Human Services to calculate and publish FMAP rates |
|
each year. The statutory formula compares the individual |
|
state's per capita income to the Nation's per capita income in |
|
order to determine the portion of Medicaid expenditures the |
|
federal government will finance in each state. The lower a |
|
state's per capita income, the greater the assistance the state |
|
receives from the federal government, so, the higher the |
|
state's FMAP. |
|
Federal statute specifies that the basic Medicaid matching |
|
rate for states will go no lower than 50 percent or higher than |
|
83 percent. Medicaid has used the basic FMAP formula since its |
|
creation, more than 50 years ago. |
|
Since the creation of the Medicaid program, Congress has, |
|
over time, created several different levels of federal |
|
financial participation or federal matching for different |
|
services, benefits, and populations. These higher levels of |
|
federal matching are exceptions to the general FMAP. |
|
For example, since the 1970s, the federal government has |
|
paid 100 percent for services furnished through Indian Health |
|
Services and tribal facilities and 90 percent for family |
|
planning services and supplies. These exceptions are higher |
|
than any state's regular FMAP and apply uniformly to all |
|
states. Today we will be discussing numerous other exceptions |
|
to the regular FMAP. |
|
In recent years, Congress has twice increased FMAPs across |
|
the board to provide temporary fiscal relief to states during |
|
recessions. Most recently, Congress added a new level of |
|
increased federal matching through the Affordable Care Act's |
|
expansion of the Medicaid program to non-disabled childless |
|
adults. For new expansion states, the Affordable Care Act |
|
included a matching rate of 100 percent for the expansion |
|
population through this calendar year, after which federal |
|
matching levels decline over time to reach 90 percent by 2020 |
|
and remain at that rate, at least under current law. |
|
I should also point out that the FMAP also serves as the |
|
basis for determining the federal government's share of |
|
expenditures for the Children's Health Insurance Program, CHIP. |
|
Section 2105(b) of the Social Security Act stipulates an |
|
Enhanced FMAP rate for both services and administration under |
|
CHIP. The E-FMAP rate reduces the state's share under the |
|
regular FMAP rate by 30 percent. Additionally, the Affordable |
|
Care Act increased the E-FMAP by 23 percentage points, not to |
|
exceed 100 percent, for fiscal years 2016 through 2019. As a |
|
result, the federal government is now financing 100 percent of |
|
the CHIP programs in 12 states. |
|
Overall, I think today's hearing presents members with an |
|
important opportunity to better understand the FMAP rate that |
|
is hardwired into the heart of the program. I also hope members |
|
will grapple with the challenges created by the current FMAP |
|
formula, including the ways that the current patchwork of |
|
federal matching arrangements impacts the integrity of the |
|
federal and state cost-sharing relationship. |
|
Today, we have one panel of knowledgeable experts from CRS, |
|
MACPAC, GAO, and HHS OIG who will present their ideas and |
|
recommendations on these issues and answer members' questions. |
|
I appreciate each of the witnesses being here today. |
|
[The prepared statement of Mr. Pitts follows:] |
|
|
|
Prepared statement of Hon. Joseph R. Pitts |
|
|
|
The Subcommittee will come to order. |
|
The Chairman will recognize himself for an opening |
|
Statement. |
|
Today's hearing will provide an opportunity for members to |
|
discuss the ``Federal Medical Assistance Percentage'' or ``F- |
|
MAP'' (FMAP) rate. The FMAP is the Federal statutory financing |
|
formula that is the basis for determining the Federal |
|
government's financial share of most Medicaid and Children's |
|
Health Insurance Program (CHIP) expenditures. |
|
While exploring the FMAP may seem like a dense topic to |
|
some, today's hearing allows members to look under the cabinet |
|
to examine Medicaid's plumbing--how money flows throughout the |
|
system. It is important for members to understand how the FMAP |
|
works, because it impacts how an estimated $545 billion in |
|
program expenditures will be spent this year. |
|
Federal law specifies the formula for calculating Federal |
|
Medical Assistance Percentages and requires the Secretary of |
|
Health and Human Services to calculate and publish FMAP rates |
|
each year. The statutory formula compares individual State's |
|
per capita income to the nation's per capita income in order to |
|
determine the portion of Medicaid expenditures the Federal |
|
government will finance in each State. The lower a State's per |
|
capita income, the greater the assistance the State receives |
|
from the Federal government--so the higher the State's FMAP. |
|
Federal statute specifies that the basic Medicaid matching |
|
rate for States will go no lower than 50% or higher than 83 |
|
percent. Medicaid has used the basic FMAP formula since its |
|
creation, more than 50 years ago. |
|
Since the creation of the Medicaid program, Congress has, |
|
over time, created several different levels of Federal |
|
financial participation, or ``federal matching'' for different |
|
services, benefits, and populations. These higher levels of |
|
federal matching are exceptions to the general FMAP. |
|
For example, since the 1970s, the Federal government has |
|
paid 100 percent for services furnished through Indian Health |
|
Services and tribal facilities and 90 percent for family |
|
planning services and supplies. |
|
These exceptions are higher than any State's regular FMAP |
|
and apply uniformly to all States. Today we will be discussing |
|
numerous other exceptions to the regular FMAP. |
|
In recent years, Congress has twice increased FMAPs across |
|
the board to provide temporary fiscal relief to States during |
|
recessions. |
|
Most recently, Congress added a new level of increased |
|
federal matching through the Affordable Care Act's expansion of |
|
the Medicaid program to non-disabled childless adults. For new |
|
expansion states, the Affordable Care Act included a matching |
|
rate of 100 percent for the expansion population through this |
|
calendar year, after which Federal matching levels decline over |
|
time to reach 90 percent by 2020--and remain at that rate, at |
|
least under current law. |
|
I should also point out that the FMAP also serves as the |
|
basis for determining the Federal government's share of |
|
expenditures for the Children's Health Insurance Program-CHIP. |
|
Section 2105(b) of the Social Security Act stipulates an |
|
Enhanced FMAP rate for both services and administration under |
|
CHIP. The E-FMAP rate reduces the State share under the regular |
|
FMAP rate by 30 percent. |
|
Additionally, the Affordable Care Act increased the E-FMAP |
|
by 23 percentage points (not to exceed 100 percent) for fiscal |
|
years 2016 through 2019. As a result, the Federal government is |
|
now financing 100 percent of the CHIP programs in 12 states. |
|
Overall, I think today's hearing presents members with an |
|
important opportunity to better understand the FMAP rate that |
|
is hardwired into the heart of the program. I also hope members |
|
will grapple with the challenges created by the current FMAP |
|
formula--including the ways that the current patchwork of |
|
Federal matching arrangements impact the integrity of the |
|
Federal and State cost-sharing relationship. |
|
Today we have one panel of knowledgeable experts from CRS, |
|
MACPAC, GAO, and HHS OIG who will present their ideas and |
|
recommendations on these issues and answer Members' questions. |
|
I appreciate each of the witnesses being here today and |
|
will now yield to the Vice Chairman of the full committee, Mrs. |
|
Blackburn. |
|
|
|
Mr. Pitts. And I yield back the balance of my time. I now |
|
recognize Mr. Schrader of Oregon for an opening statement. |
|
Mr. Schrader. Thank you, Mr. Chairman. I will probably |
|
reserve most of my comments for the question period but I |
|
wanted to yield some time to Mr. Luja AE1n. |
|
Mr. Luja AE1n. Mr. Chairman, thank you so very much and to |
|
our ranking member, I really appreciate the time today. |
|
I care deeply about these programs. As we see the impact to |
|
people all across America, this landmark program makes a |
|
difference in the lives of the poor, our seniors, people with |
|
disabilities, and truly provides them the peace of mind that |
|
they can access affordable care without fear of financial ruin. |
|
We have to be mindful of that. |
|
One in three children in our country receive coverage |
|
through Medicaid and the Affordable Care Act's expansion of |
|
this program is strengthening coverage throughout the United |
|
States. In my home State of New Mexico, more than 250,000 |
|
people have benefitted from the ACA's Medicaid expansion. |
|
In New Mexico, we have also recently seen what happens to |
|
people when they can't receive the care that they need. More |
|
than 2 years ago, New Mexico's Behavioral Health System was |
|
needlessly upended by the state when they suspended Medicaid |
|
payments to 15 providers. This resulted in disruptions and gaps |
|
in patients' care. |
|
On Monday, just a few days ago or just 2 days ago, ten |
|
additional providers were cleared of fraud. In total, 13 have |
|
now been exonerated. This manufactured crisis which has |
|
impacted some of New Mexico's most vulnerable never should have |
|
occurred and left our Behavioral Health System in shambles. |
|
It takes decades to build a strong system of care in New |
|
Mexico's largely rural underserved areas. Where sole providers |
|
become vital to the fabric of our community, those |
|
relationships and developing that trust with patients is |
|
critical and we have to rebuild that system now. |
|
To achieve that goal, I am finalizing a bill that would |
|
encourage states like New Mexico to make the necessary |
|
investments in their Behavioral Health Systems when Congress |
|
ask states to update and modernize their infrastructure for |
|
enrollment. We provided states with an Enhanced FMAP to do just |
|
that. If we want states to invest in behavioral health, we |
|
should provide an enhanced federal matching rate to prioritize |
|
these investments. The United States has never supported mental |
|
health in this way. Especially with the expansion of Medicaid |
|
across the country, we must ensure that states continue to |
|
improve their capacity to provide mental health services. |
|
I look forward to the testimony and discussing how we can |
|
use FMAP to strengthen our Behavioral Health System. |
|
And with that, Mr. Chairman, I would yield back the |
|
balance of my time to Mr. Schrader. |
|
Mr. Schrader. Thank you very much. Anyone else on the |
|
Democratic side? Ms. Matsui. |
|
Ms. Matsui. Thank you very much for yielding and I thank |
|
the witnesses for being here today and the chairman for having |
|
this hearing. |
|
For the past 50 years, the Medicaid program has |
|
successfully improved the ability of lower income Americans to |
|
access essential health services. Today, more than 72 million |
|
Americans depend on Medicaid and CHIP for their health |
|
insurance. The vast majority of these enrollees are children, |
|
the disabled, or the elderly. |
|
In addition to improving healthcare access, Medicaid is |
|
notable for its program efficiency. Medicaid provides more |
|
comprehensive benefits than private insurance and provides |
|
those benefits at lower out-of-pocket costs. In addition, |
|
Medicaid per beneficiary costs are lower than per beneficiary |
|
costs for Medicare and private insurance and those costs are |
|
growing far more slowly than either Medicare or private |
|
insurance. |
|
The Medicaid program continues to improve its efficiency |
|
and its demonstration projects allow the states the flexibility |
|
to test new models of delivery that improve program value. |
|
Instead of talking about ways to reduce Medicaid, we should be |
|
talking about ways to strengthen Medicaid, to expand coverage, |
|
to improve quality of care and, in turn, improve health |
|
outcomes for millions of Americans. Thank you and I yield back |
|
to Dr. Schrader. |
|
Mr. Schrader. Anyone else on the Democratic side? Mr. |
|
Pallone. |
|
Mr. Pitts. You will get your full time. |
|
Mr. Schrader. Mr. Pallone, I will give Mr. Sarbanes an |
|
opportunity then you will get your full time. |
|
Mr. Pallone. Oh, sure. |
|
Mr. Schrader. Mr. Sarbanes. |
|
Mr. Sarbanes. I will be very quick. I am looking forward to |
|
the testimony. |
|
I had the opportunity for about 18 years as an attorney to |
|
work with retirement communities, nursing homes, assisted |
|
living facilities in the State of Maryland and saw how critical |
|
the resource of Medicaid is for our seniors. And so keeping |
|
this program strong and also exploring opportunities to |
|
innovate with it and figure out how the program can support |
|
seniors in a number of different settings, as we move forward |
|
and the opportunity to do that in a way that can also save some |
|
of the costs and be efficient I think is something we want to |
|
explore. |
|
So, it is a really important program and this particular |
|
formula for funding has worked overall very well. So, we look |
|
forward to your testimony so we can understand that more and |
|
think about the potential for future development of the |
|
program. |
|
I yield back. |
|
Mr. Schrader. I yield back our time, Mr. Chairman. |
|
Mr. Pitts. The chair thanks the gentleman. I now recognize |
|
the vice chair of the full committee, Mrs. Blackburn, for 5 |
|
minutes for opening statement. |
|
|
|
OPENING STATEMENT OF HON. MARSHA BLACKBURN, A REPRESENTATIVE IN |
|
CONGRESS FROM THE STATE OF TENNESSEE |
|
|
|
Mrs. Blackburn. Thank you, Mr. Chairman. And I want to |
|
welcome you all and thank you for being here. |
|
This is an issue that we continue to look at and review and |
|
it is appropriate that we do. When I am at home and in my |
|
district, one of the things I hear about most often are the |
|
efficiencies and the inefficiencies of working through the |
|
Medicaid delivery system which, in our state is TennCare. You |
|
all probably know it and know the stories of TennCare well. |
|
What we need to do as we continue to review these funding |
|
formularies and the mechanisms, transparency is important, |
|
continued oversight is important, integrity in the program is |
|
something that is important. I think another thing that is a |
|
topic for discussion as we look at the formulary and what the |
|
basis ought to be is saying is it time to give Medicaid back to |
|
the states for the states to administer this program. That is |
|
another way to look at it. And we will be interested to hear |
|
your thoughts on that. |
|
Many of our governors and many of our state elected |
|
officials would like to see us do that. They think they could |
|
be more efficient and Ms. Matsui mentioned the opportunity for |
|
some to innovate in their states. And yes, indeed, looking at |
|
new flexibilities that allow innovation is something that maybe |
|
we need to have greater discussion about that. |
|
So, welcome to all of you and thank you. And Mr. Chairman, |
|
I will yield to Mr. Shimkus, it looks like, is seeking time. |
|
Yield to Mr. Shimkus. |
|
Mr. Shimkus. Thank you. I appreciate my colleague from |
|
Tennessee. |
|
I am just going to throw something on the table. I have got |
|
questions later on. But Mr. Chairman, I was visited by a |
|
delegation of businessmen from Puerto Rico last night and they |
|
have--and I just want to raise this because I think for the |
|
average member this financial crisis, we are now starting to at |
|
least know a little bit about it. But since we are on Medicaid, |
|
I was told that they have a $300 million cap on spending. They |
|
are not in the Medicaid system. They don't have FMAP. And there |
|
is an impending cliff coming in April of 2017 that I think is |
|
worthy of our attention and maybe a hearing and a discussion |
|
because if what I was told was true, it is an impending |
|
additional disaster for that part of our country that really |
|
doesn't have a voting member of the House of Representatives. |
|
So with that, I will throw that out and I will yield back |
|
to my colleague. |
|
Mrs. Blackburn. I thank the gentleman. Anyone else seeking |
|
time before I yield it back to the chairman? |
|
Mr. Chairman, I yield back. |
|
Mr. Pitts. The chair thanks the gentlelady and I recognize |
|
the ranking member of the full committee, Mr. Pallone, for 5 |
|
minutes for an opening statement. |
|
|
|
OPENING STATEMENT OF HON. FRANK PALLONE, JR., A REPRESENTATIVE |
|
IN CONGRESS FROM THE STATE OF NEW JERSEY |
|
|
|
Mr. Pallone. Thank you, Mr. Chairman and thanks for holding |
|
the hearing for the witnesses being here today. |
|
I believe the government exists to help all Americans |
|
succeed and improving and strengthening Medicaid for |
|
generations to come continues to be a primary goal of mine. |
|
Medicaid is not a welfare program. It is a health insurance |
|
program that more Americans depend on than any other single |
|
federal health program. In fact, Medicaid provides more than |
|
one in three children with a chance at a healthy start in life |
|
and one in seven Medicare seniors are actually also Medicaid |
|
seniors. The truth is, the overwhelming majority of the more 71 |
|
million Medicaid beneficiaries are children, the elderly, the |
|
disabled, and pregnant women, all our most vulnerable |
|
populations. |
|
Medicaid was designed at the federal level to expand and |
|
contract according to a state's need and that is a tenant we |
|
must protect and improve, not reverse. And despite the |
|
incredibly complex nature of its shared federal and state |
|
financing, Medicaid is an efficient program, its cost per |
|
beneficiary is substantially lower than private insurance and |
|
Medicare and in recent years, these costs have grown far more |
|
slowly. |
|
The facts also show that Medicaid has a lower improper |
|
payment rate than many of our federal health programs, all of |
|
which cover less people. |
|
Every single state Medicaid program has undertaken projects |
|
testing new models of care delivery that promote quality and |
|
value in the Medicaid program. In fact, the Medicaid program is |
|
often called the innovation incubator. |
|
So, as you know more about Medicaid's financing structure |
|
or FMAP today, let's think how to build on these efforts. That |
|
is the right way to promote a value-based Medicaid program for |
|
the future. FMAP may not be perfect but merely looking at |
|
baselines, growth factors, and state contributions ignores the |
|
most critical issue, which is providing care in the most |
|
efficient way possible to some of our most complicated |
|
populations, the tens of millions of low-income vulnerable |
|
beneficiaries that rely on Medicaid and the healthcare |
|
providers and plans that serve them. |
|
I yield back, unless someone else--I think our other |
|
members have all had an opportunity, Mr. Chairman, so I yield |
|
back. |
|
Mr. Pitts. The chair thanks the gentleman. |
|
That concludes the opening statements. As always, all |
|
members' written opening statements will be made a part of the |
|
record. |
|
We have one panel with us today, four witnesses. Let me |
|
introduce them in the order of their testimony. |
|
First of all, Allison Mitchell, Analyst in Health Care |
|
Financing, Congressional Research Service. Thank you for |
|
coming. Secondly, Dr. Anne Schwartz, Executive Director, |
|
Medicaid and CHIP Payment and Access Commission, MACPAC. Thank |
|
you for coming. Carolyn Yocom, Director of Health Care, |
|
Government Accountability Office, GAO. Thank you for coming. |
|
And John Hagg, is it? Hagg, Director of the Medicaid Audits, |
|
Office of Inspector General, U.S. Department of Health and |
|
Human Services. |
|
Thank you all for coming. You will each be given 5 minutes |
|
to summarize your testimony. Your written testimony will be |
|
made a part of the record. |
|
So, at this point, the chair recognizes Ms. Mitchell, for 5 |
|
minutes for her summary. |
|
|
|
STATEMENTS OF ALISON MITCHELL, ANALYST IN HEALTH CARE |
|
FINANCING, CONGRESSIONAL RESEARCH SERVICE; ANNE SCHWARTZ, |
|
PH.D., EXECUTIVE DIRECTOR, MEDICAID AND CHIP PAYMENT AND ACCESS |
|
COMMISSION; CAROLYN YOCOM, DIRECTOR OF HEALTH CARE, GOVERNMENT |
|
ACCOUNTABILITY OFFICE; AND JOHN HAGG, DIRECTOR OF THE MEDICAID |
|
AUDITS, OFFICE OF INSPECTOR GENERAL, U.S. DEPARTMENT OF HEALTH |
|
AND HUMAN SERVICES |
|
|
|
STATEMENT OF ALISON MITCHELL |
|
|
|
Ms. Mitchell. Chairman Pitts, members of the subcommittee, |
|
thank you for the opportunity to appear before you today to |
|
provide an overview of the Federal Medical Assistant |
|
Percentage, or the FMAP, and the exceptions to the FMAP. |
|
Medicaid is financed by both the federal government and the |
|
states and the federal share of Medicaid expenditures is |
|
determined by the FMAP. The FMAP varies by state and it has a |
|
minimum of 50 percent and a statutory maximum of 83 percent. |
|
And for a state with a 60 percent FMAP, the state gets 60 cents |
|
back from the federal government for every dollar it spends on |
|
its Medicaid program. |
|
The FMAP is also used to determine the federal share of |
|
other federal programs, such as the Temporary Assistance for |
|
Needy Families contingency funds and the FMAP is also used to |
|
calculate the Enhanced FMAP or E-FMAP, which determines the |
|
federal share for the state Children Health Insurance Program |
|
or CHIP. |
|
The FMAPs are calculated annually and they vary according |
|
to each state's per capita income. So, states with high per |
|
capita income receive lower FMAP or matching rates and states |
|
with low per capita income receive higher matching rates. |
|
Currently, in fiscal year 2016, regular FMAP rates range |
|
from 50 percent in 13 states to 74 percent in Mississippi. And |
|
the E-FMAP used by CHIP is higher than the regular FMAP and it |
|
is determined by reducing the state share under the FMAP by 30 |
|
percent. And for fiscal year 2016 through 2019, there is a 23 |
|
percentage point increase in the E-FMAP. That means the current |
|
statutory range for the E-FMAP is 88 percent to 100 percent and |
|
in fiscal year 2016, 12 states are receiving that 100 percent |
|
E-FMAP. |
|
The per capita income amounts used in the FMAP formula are |
|
equal to the average of the three most recent calendar years of |
|
data from the Department of Commerce. This helps to moderate |
|
the fluctuations in states' FMAP rates over time. Also, the per |
|
capita income amounts used to calculate the FMAP rates are |
|
several years old by the time the FMAP goes into effect. |
|
The FMAP is impacted by each state's income and population |
|
relative to the national average. The impact of the national |
|
economic downturn or upturn on a particular state will be |
|
related to that structure of that state's economy. |
|
The FMAP changes from year to year for most states and |
|
these changes are often within one percentage point. However, |
|
even these small changes can have major budgetary implications. |
|
The exceptions to the regular FMAP have been made for |
|
certain states' situations, populations, providers, and |
|
services. There are currently more than 20 exceptions to the |
|
FMAP. Some of these are quite old and some of them are newer. |
|
For instance, since the beginning of the Medicaid program, most |
|
administrative services have been matched at a 50 percent for |
|
all states and starting in the 1970s, services provided to |
|
Medicaid enrollees at Indian Health Service facilities have |
|
been reimbursed at 100 percent. |
|
Also, the District of Columbia's FMAP rate is not |
|
determined according to the statutory formula. It is set in |
|
statute at 70 percent and that has been the case since 1998. |
|
And the Patient Protection and Affordable Care Act added a |
|
couple of new FMAP exceptions. The main one there is the FMAP |
|
for the matching rate for the newly eligible individuals under |
|
the ACA Medicaid expansion. For these individuals, states |
|
receive 100 percent matching for 2014 through 2016 and that |
|
phases down to 90 percent in 2020 and subsequent years. |
|
The federal share of Medicaid expenditures used to be about |
|
57 percent on average across all states in a typical year. |
|
However, with the exceptions to the FMAP added by the ACA, this |
|
has increased and in 2014, fiscal year 2014, the federal |
|
government paid about 60 percent of Medicaid expenditures on |
|
average across all the states. |
|
This concludes my statement and I would be happy to answer |
|
questions at the appropriate time. |
|
[The prepared statement of Alison Mitchell follows:] |
|
|
|
|
|
|
|
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] |
|
|
|
|
|
Mr. Pitts. The chair thanks the gentlelady and now |
|
recognizes Dr. Schwartz, for 5 minutes for your summary. |
|
|
|
STATEMENT OF ANNE SCHWARTZ |
|
|
|
Ms. Schwartz. Good morning, Chairman Pitts and the members |
|
of the subcommittee on Health. As MACPAC's Executive Director, |
|
my testimony today reflects the consensus views of the |
|
commission itself anchored in a body of analytic work over the |
|
past 5 years and we appreciate the opportunity to share |
|
MACPAC's views this morning. |
|
At the request of the leadership of this subcommittee and |
|
your colleagues in the Senate, MACPAC is engaged in a long-term |
|
work plan focused on advising Congress about policies and |
|
financing reforms to ensure Medicaid sustainability. To date, |
|
we have focused on documenting trends in Medicaid expenditures, |
|
looking at the drivers of this spending and considering the |
|
incentives created by the current system of financing. |
|
As others have already described, state Medicaid programs |
|
received federal fund to match the funds they spend on health |
|
services to Medicaid beneficiaries and its financing |
|
arrangement goes back to the program's very beginnings 50 years |
|
ago. |
|
Today, the federal share is determined by the FMAP with |
|
higher matching rates to states that have lower per capita |
|
incomes relative to the national average and vice-versa with |
|
exceptions for certain populations, providers, and services. |
|
Spending for administration is general matched at 50 percent. |
|
CHIP has its own match rates, known as the Enhanced FMAP, which |
|
is substantially higher than those under Medicaid, in some |
|
cases at 100 percent. |
|
At various points in the program's history, congressional |
|
regulatory action have increased the FMAP for specific |
|
activities. For example, to help execute certain program |
|
functions, such as implementation of modernized eligibility and |
|
enrollment systems to create stronger incentives for states to |
|
provide optional benefits and to encourage states to expand |
|
eligibility to optional groups, such as women diagnosed with |
|
breast and cervical cancer. |
|
Enhanced match has also been used to provide fiscal relief |
|
to states during economic downturns or when affected by |
|
disasters. In addition, increasing the federal match can allow |
|
Congress to make policy changes without imposing additional |
|
costs on states, for example, as was the case with the required |
|
increase in payments to primary care physicians in 2013 and |
|
2014. |
|
As others on the panel will note, this system of financing |
|
has been criticized for providing open-ended amounts of federal |
|
funds and for not incentivizing states to be efficient. |
|
Moreover, it can encourage states to broaden Medicaid to |
|
include other health activities, where possible, in order to |
|
draw down federal funds. |
|
On the other hand, these incentives, while strong, are not |
|
absolute. States may not claim federal share unless they spend |
|
state dollars, raised from legal sources, on activities that |
|
are legally matchable. Mindful of their own budget constraints, |
|
as well as other political and economic factors that shape |
|
their health care markets and the design of their Medicaid |
|
programs, states respond differently at different times and in |
|
different circumstances. |
|
So, let me provide a few examples. States do make informed |
|
choices about the design of their programs and thus, they don't |
|
always take up the opportunity to draw enhanced match. Section |
|
2703 of the ACA provided authority for states to create health |
|
homes integrating care for people with chronic conditions and |
|
mental health conditions and it provided a 90 percent federal |
|
match for 2 years and fewer than half of the states have done |
|
so, with only 20 states and the District of Columbia adopting |
|
the model as of December 2015. |
|
Second, because states must raise state share, they do not |
|
always take advantage of all federal dollars that are available |
|
to them. |
|
In the case of CHIP, of the $21.1 billion in federal funds |
|
appropriated for fiscal year 2015, only $11.3 billion was |
|
provided to states in allotments based on their prior year |
|
spending. |
|
In addition to the other criticisms under the matching |
|
formula that will be discussed by others on the panel, I would |
|
add several other concerns that MACPAC has identified. First, |
|
the differential between the federal match for services and |
|
administration exerts downward pressure on states' willingness |
|
to invest in activities such as measuring utilization and |
|
quality, collecting and analyzing data, and ensuring program |
|
integrity. In the 37 states where health services are matched |
|
at greater than 50 percent, states can increase the total |
|
Medicaid budget by prioritizing spending for services over |
|
administration. |
|
The federal government does provide enhanced matching funds |
|
for some administrative activities but enhanced match is not |
|
available for others that could improve efficiency and promote |
|
value. For example, the differential between the two match |
|
rates creates a disincentive for states to focus on prevention |
|
of fraud and abuse. Such functions are matched at 50 percent, |
|
while the activities of the Medicaid Fraud Control Unit which |
|
are aimed at detecting fraud and abuse after they have occurred |
|
are matched at 75 percent. |
|
Over the next several months, MACPAC will be focusing |
|
intensively on program financing and design questions. Our |
|
analysis will consider design questions and will also consider |
|
the impact of these approaches on states, plans, providers and |
|
beneficiaries. We look forward to sharing this work in our June |
|
report. |
|
[The prepared statement of Anne Schwartz follows:] |
|
|
|
|
|
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] |
|
|
|
|
|
|
|
Mr. Pitts. The chair thanks the gentlelady and now |
|
recognizes Ms. Yocom, for 5 minutes for her summary. |
|
|
|
STATEMENT OF CAROLYN YOCOM |
|
|
|
Ms. Yocom. Thank you. It is a pleasure to be here today to |
|
discuss the Medicaid formula, and GAO's work surrounding this |
|
issue. |
|
As we have talked about, the FMAP formula is based on a |
|
state's per capita income in relation to the national average. |
|
And it is over a 3-year period, which smooths out the |
|
fluctuations in the business cycle and focuses on longer-term |
|
trends. This is helpful to states in terms of their budgets and |
|
budgetary planning. |
|
In prior work, we have noted concerns regarding how FMAP |
|
formula allocates funds across the states, including during |
|
times of recession or economic downturn. My statement today |
|
focuses on the FMAP and options for more equitably allocating |
|
Medicaid funds across states and methods of better targeting |
|
increased assistance to states during an economic downturn. |
|
With regard to the more equitable allocation of Medicaid |
|
funds across states, per capita income is a poor proxy for |
|
states' fiscal capacity, as well as for the size and |
|
composition of a state's population in need of Medicaid. First, |
|
per capita income does not fully measure state resources. It |
|
includes some things, like wages, grants, and interest, but it |
|
does not include other resources such as corporate income. |
|
Second, per capita income does not take into account |
|
differences across the states in the health care service needs |
|
of low-income people, nor does it include any measure of |
|
geographic difference in the cost of providing such services. |
|
As an alternative to per capita income, GAO has identified |
|
three measures that could be used to allocate Medicaid funding |
|
more equitably. Two of these measures account for service |
|
demand and they also account for geographic cost differences. |
|
This improves equity among beneficiaries by ensuring that the |
|
level of services across states has the ability to offer a |
|
comparable level of services for each person in need. The third |
|
measure accounts for state resources and this improves taxpayer |
|
equity by ensuring that taxpayers in poorer states are not more |
|
heavily burdened than those in wealthier ones. These three |
|
measures could be combined to provide a basis for allocating |
|
Medicaid funds in a more equitable manner than what currently |
|
occurs using the FMAP. |
|
With regard to targeting increased assistance to states |
|
during recessions and other economic downturns, Congress has |
|
acted on multiple occasions to provide states with temporary |
|
increases in the FMAP. Such assistance is important, for during |
|
economic downturns, Medicaid enrollment often increases, while |
|
available state revenues decline. |
|
At the request of Congress, GAO was asked to consider |
|
methods of assisting states during economic downturns. We |
|
recommended that Congress consider enacting an FMAP formula |
|
that provides automatic timely and temporary FMAP assistance to |
|
states in response to an economic downturn. We developed a |
|
prototype formula that would automatically start and end |
|
assistance and it would target the amount of such assistance |
|
based on the extent to which each state is affected by a |
|
particular downturn. |
|
Our prototype formula uses a monthly employment to |
|
population ratio and it begins when a threshold number of |
|
states experience declines in this ratio. This automatically |
|
triggers the start of the FMAP assistance. And once triggered, |
|
the assistance is calculated based on two factors. First, on |
|
increases in state unemployment. This serves as a proxy for |
|
changes in Medicaid enrollment. And then secondly for decreases |
|
in wages and salaries and this serves as a proxy for declines |
|
in available state revenue. |
|
Ending the temporary FMAP would be based on the employment- |
|
to-population ratio but with the ability to gradually return |
|
states to their regular FMAPs. |
|
In conclusion, our work has found that alternatives to the |
|
current FMAP could more equitably allocate funds to states and |
|
provide additional support during the economic downturns. |
|
This concludes my prepared statement. I would be pleased to |
|
answer questions at the appropriate time. |
|
[The prepared statement of Carolyn Yocom follows:] |
|
|
|
|
|
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] |
|
|
|
|
|
Mr. Pitts. The chair thanks the gentlelady and now |
|
recognizes Mr. Hagg, for 5 minutes for his opening statement. |
|
|
|
STATEMENT OF JOHN HAGG |
|
|
|
Mr. Hagg. Good morning, Chairman Pitts and other |
|
distinguished members of the committee. Thank you for the |
|
opportunity to testify about the Officer of Inspector General's |
|
work associated with the Federal Medical Assistance Percentage |
|
Matching Rates. My statement describes two vulnerabilities |
|
associated with the federal-state partnership that governs the |
|
financing of the Medicaid program. |
|
First, in certain areas of enhanced matching rates, OIG has |
|
seen states claim federal reimbursement for expenditures that |
|
do not qualify. Second, in some instances, we have seen states |
|
use financing mechanisms to shift costs to the federal |
|
government. I will briefly discuss each of these issues. |
|
Most Medicaid expenditures are eligible for federal |
|
reimbursement at their regular matching rate. The regular FMAP |
|
rate varies by state and, as said earlier today, cannot be |
|
lower than 50 percent or higher than 83 percent. There are |
|
numerous exceptions, however, that allow for the use of |
|
enhanced rates. For example, family planning services are |
|
reimbursed at a 90 percent FMAP rate. Enhanced FMAP rates |
|
provide states with additional federal funding for specified |
|
populations and services but they also create vulnerabilities |
|
that expenditures could be claimed incorrectly. |
|
The OIG has conducted audits to determine if expenditures |
|
were included in the correct enhanced rate categories. In |
|
general, we have found instances where states incorrectly |
|
claimed expenditures in one of the enhanced rate categories, |
|
instead of properly claiming the expenditures at the lower |
|
regular FMAP rate. As an example, we have found many cases |
|
where states use the 90 percent enhanced family planning rates |
|
for services that were Medicaid eligible but did not qualify as |
|
family planning. In total, we identified more than $82 million |
|
that states received inappropriately. |
|
In addition to vulnerabilities that exist with enhanced |
|
FMAP categories, the shared nature of Medicaid financing |
|
provides opportunities for states to shift cost and distort the |
|
federal-state cost-sharing partnership. While mechanisms such |
|
as provider taxes, intergovernmental transfers, and inflated |
|
payment rates increase state funds, they distort statutorily |
|
determined FMAP rates and undermine the federal-state |
|
partnership in financing the Medicaid program. |
|
In the 2014 review of health care provider taxes, we found |
|
that a gross receipts tax on Medicaid managed care |
|
organizations in one state appeared to be an impermissible |
|
health care related tax under federal requirements. Using this |
|
tax, the state obtained nearly $1 billion in federal Medicaid |
|
funds from 2009 to 2012. CMS issued guidance to states in July |
|
2014 to clarify its policy. We are currently performing work to |
|
determine if states are in compliance with this guidance. |
|
State policies that inflate federal costs for Medicaid are |
|
not new. In a series of reports from 2000 to 2005, we found |
|
numerous examples in which states used intergovernmental |
|
transfers to increase the amount of Medicaid expenditures the |
|
federal government would pay. In some cases, states transferred |
|
the additional federal money to their general treasury to be |
|
used for other purposes. Both Congress and CMS took action to |
|
close this loophole. While the changes dramatically improved |
|
the situation, they did not entirely eliminate the problem. |
|
Collectively, the findings of our work over a number of years |
|
suggest that improvements are still needed to safeguard federal |
|
Medicaid funds, including a definitive regulation linking |
|
payments for public providers to the actual cost of providing a |
|
service. |
|
In conclusion, the federal and state governments share |
|
responsibility for operating the Medicaid program and for the |
|
integrity of the dollars invested. Given projected growth in |
|
Medicaid, it is critical that CMS and states focus on |
|
strengthening program integrity. OIG is committed to providing |
|
effective oversights to help ensure that inappropriate payments |
|
are detected and that eligible beneficiaries receive the needed |
|
and appropriate health care services. |
|
I would be happy to answer your questions. |
|
[The prepared statement of John Hagg follows:] |
|
|
|
|
|
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] |
|
|
|
|
|
Mr. Pitts. The chair thanks the gentleman. That concludes |
|
the opening statements of the witnesses. I will begin the |
|
questioning and recognize myself for 5 minutes for that |
|
purpose. |
|
Ms. Yocom, GAO has offered alternatives for allocating |
|
federal Medicaid funding in a more equitable way. Can you |
|
explain how GAO considers equity when thinking about the |
|
Medicaid funding formula? And can you explain how or why some |
|
states are advantaged and others are disadvantaged by the |
|
current FMAP formula? |
|
Ms. Yocom. Yes, we look at equity from two perspectives. |
|
The first is that of the beneficiary and making sure that the |
|
state has the capacity to provide the same level of service as |
|
across all the states. It doesn't mean that the state chooses |
|
to but it does mean that that capacity is there. |
|
And then secondly, we look from the perspective of the |
|
taxpayer and so that you make sure that a wealthier state is |
|
not paying more or less than a poorer state, that it is in |
|
relation to what is available for the state to fund the |
|
program. |
|
With regard to advantages and disadvantages of the formula |
|
itself, yes, right now the floor, as I believe Dr. Schwartz |
|
mentioned, the 50 percent floor of the FMAP does mean that some |
|
states are propped up with more assistance than other states. |
|
To date, no state has reached the top of the matching rate. |
|
There also is some research out there that shows that the |
|
matching formula is showing more and more compression to that |
|
50 percent level. |
|
So, it is a mixed bag for the states. |
|
Mr. Pitts. Thank you. |
|
Dr. Schwartz, almost a year ago, I, along with Chairman |
|
Upton and Chairman Hatch asked MACPAC to engage in developing |
|
policy options to ensure the sustainability of the Medicaid |
|
program. However, it was not until MACPAC's most recent meeting |
|
a few weeks ago that staff even briefed the commissions on old |
|
Medicaid ideas from the 1980s and 1990s. And with all due |
|
respect, why has this taken so long? What could be more |
|
important than developing solutions to strengthen Medicaid and |
|
CHIP? |
|
Ms. Schwartz. Thank for that question. |
|
We began our discussion of financing alternatives actually |
|
beginning in February of last year with this session to discuss |
|
a range of alternatives. And in that particular session, we |
|
spoke a lot about shared savings. Subsequent to that, we spent |
|
time at every commission meeting since then: May, September, |
|
October, December, and again, as you say in January, focusing |
|
on spending trends, helping understand the context, |
|
understanding the policy levers that are available to state and |
|
federal governments, to address concerns about spending, and to |
|
understand the drivers of that spending. |
|
So, I have a long list of activities that we have |
|
undertaken, some issue briefs that we have published, the work |
|
that is leading up for our publication in our report to |
|
Congress in June and I would be happy to share that with you |
|
and brief your staff in detail about those activities. |
|
Mr. Pitts. All right, thank you. |
|
Mr. Hagg, your testimony noted that multiple Inspector |
|
General audits found repeated state errors in claiming the 90 |
|
percent Enhanced Family Planning Match and, as a result, OIG |
|
recommended that 19 states return more than $82 million to |
|
taxpayers. Was this money ever returned? |
|
Mr. Hagg. I believe it has been. Our reports are issued to |
|
the states. We make recommendations to the states. And if we |
|
found overpayments, we would recommend they pay that money |
|
back. CMS, as the action official, would work with the states |
|
to get that money back, assuming CMS concurs with our |
|
recommendations. And I think in most cases, they have. |
|
Mr. Pitts. Do you know why CMS didn't catch states' errors |
|
in claiming federal financial participation before the claims |
|
were paid? |
|
Mr. Hagg. Not definitively. CMS has different controls in |
|
place. They could probably more fully answer that question as |
|
to why they wouldn't catch errors. Based on what I know, they |
|
have staff located throughout the country who receive |
|
expenditures from the state on a quarterly basis. They are the |
|
front line for trying to review and identify any problems that |
|
might be out there. But of course, it is billions of dollars |
|
and they have a short amount of time to---- |
|
Mr. Pitts. Yes, maybe part of the problem could be a lack |
|
of specific federal statutory and regulatory definition of what |
|
family planning services are. |
|
Ms. Mitchell, the Speaker, the President, and members of |
|
the House have noted the financial crisis in Puerto Rico. Mr. |
|
Shimkus earlier mentioned Medicaid in Puerto Rico. Can you |
|
briefly discuss how Puerto Rico's program compares or is |
|
different than an average state's Medicaid program? |
|
Ms. Mitchell. Sure. So, Puerto Rico and all five |
|
territories, the Medicaid program is financed a bit |
|
differently. Rather than the open-ended funding that states |
|
receive, the territories get caps on the funds. So, they have |
|
an annual cap. The ACA provided some additional funding that is |
|
available to the territories, and I believe that was the fiscal |
|
cliff that was referred to earlier is due to that funding. It |
|
was about $6.5 billion and the territories have through 2019 to |
|
spend that money but it looks like Puerto Rico is going to |
|
spend through that faster than that. And their matching rate |
|
for the territories is set at 55 percent. It does not go |
|
through the statutory formula for the FMAP. |
|
Mr. Pitts. Thank you. My time has expired. |
|
The chair recognizes Mr. Schrader for 5 minutes for |
|
questions. |
|
Mr. Schrader. Thank you, Mr. Chairman. I appreciate that. |
|
Ms. Mitchell, would you say that the rates for Medicaid |
|
reimbursement are primarily cost-based? |
|
Ms. Mitchell. Sorry, could you say that? |
|
Mr. Schrader. The rates that are set for Medicaid |
|
reimbursement are primarily cost-based? |
|
Ms. Mitchell. The provider rates? |
|
Mr. Schrader. Yes. |
|
Ms. Mitchell. Well, states set their own provider rates. |
|
They have a lot of discretion in setting their provider rates. |
|
Mr. Schrader. I apologize. No, I am talking about when you |
|
reimburse a state, it is based on the costs that are submitted |
|
by the state. Is that correct? |
|
Ms. Mitchell. Oh, yes. I am sorry. Yes, so there is a |
|
quarterly process where states, for every quarter, submit |
|
estimates on how much they are going to spend and they are |
|
provided an amount of money to draw down throughout the |
|
quarter. |
|
Mr. Schrader. Right. |
|
Ms. Mitchell. And at the end of the quarter, they have to |
|
submit documentation for the actual expenditures. |
|
Mr. Schrader. I get that. |
|
Ms. Schwartz, do you think that is a good way to reimburse, |
|
just based on cost rather than quality or what they are |
|
actually getting for the type of service that you are paying |
|
for? |
|
Ms. Schwartz. I guess as I noted in my testimony, that the |
|
FMAP, with the exception of the exceptions, is neutral on the |
|
type of spending. And you could certainly move to a system in |
|
which you valued certain services higher. It would be |
|
complicated but it is an area that could be tested on a smaller |
|
scale. I think doing that nationally would be exceedingly |
|
difficult across the many populations and the many services the |
|
Medicaid program offers. |
|
Mr. Schrader. I think that is why we have a number of |
|
waivers, so that each state can figure out what program |
|
probably works best for them, as long as it is officially |
|
audited, I think. |
|
Ms. Yocom, I am actually concerned about your report. Your |
|
report focuses on paying more for costs. And I think it is |
|
going to be a big additional cost to the United States |
|
taxpayer. The geographic diversity is purely cost-based. Where |
|
is the geographic diversity in your report regarding better |
|
quality of care in certain parts of the country versus other |
|
parts of the country for the dollars that are actually spent? |
|
That would be, I think, of great interest to the consumer, both |
|
the person getting the health care, as well as the taxpayer. |
|
Ms. Yocom. Yes. Our report does focus on geographic |
|
differences. And to a certain extent, state spending itself |
|
reflects some of those differences. |
|
Mr. Schrader. But that just reflects the cost. It doesn't |
|
reflect what you are getting for that. Is that correct? |
|
Ms. Yocom. That is correct. |
|
Mr. Schrader. OK. I think that is the problem, Mr. Chairman |
|
and members of the committee, that we need to be focusing on. |
|
Say what you will about the ACA but regardless of that, I think |
|
the focus of health care going forward in our country is going |
|
to be about getting bigger bang for the buck. The reports from |
|
OIG and GAO, I think try and get at that in some ways but I |
|
think they are a little outmoded. Nowadays for health care, we |
|
need to be looking at better ways to do things. |
|
The coordinated care model pioneered in my state and |
|
several other states I think is something I would like to see |
|
some of these reports start to focus on. It is complicated. The |
|
formula proposed by Ms. Yocom is also pretty complicated, if I |
|
look at it closely. So, I would like to look at that quality |
|
part of the reimbursement. |
|
Mr. Hagg, given some of the uses of the Medicaid dollars |
|
you have identified that don't seem to fit the classic category |
|
of Medicaid services, does seem kind of a play on what the |
|
chairman is talking about. Does CMS Medicaid actually have |
|
adequate revenues to police the program? |
|
Mr. Hagg. Well, that is a big job, for sure. As I said |
|
before, CMS could probably provide a better answer about the |
|
resources they have and the way they use those resources right |
|
now to oversee state expenditures or additional resources they |
|
might need. |
|
I know they have staff located throughout the country who |
|
receive the state expenditures on a quarterly basis. They are |
|
the front line for the first review but, again, we are talking |
|
about hundreds of billions of dollars in a short amount of time |
|
that they have to review those expenditures. |
|
Mr. Schrader. But it sounds like they could use a few more |
|
dollars. |
|
Out of the five or six recommendations you make, are there |
|
two or three you would like or think Congress should |
|
particularly focus on in working with CMS to review? |
|
Mr. Hagg. Well, specifically, if you are talking about |
|
trying to make sure expenditures are in the correct enhanced |
|
FMAP categories, bottom line, it really comes down to states |
|
doing a better job and taking better care and making sure that |
|
those expenditures are claimed appropriately. It is the state's |
|
job to do that. There is no way that CMS or any oversight is |
|
going to be able to get to every single layer that might be out |
|
there. So, states need to know their responsibilities and make |
|
sure that they claim properly. |
|
From CMS' standpoint, it probably would be good for CMS to |
|
try to reinforce with the states what the states' |
|
responsibilities are so the states clearly know the importance |
|
of properly claiming. |
|
Mr. Schrader. Very good. With that, I yield back, Mr. |
|
Chairman. |
|
Mr. Pitts. The chair thanks the gentleman and now |
|
recognizes the vice chair of the full committee, Mrs. |
|
Blackburn, for 5 minutes for questioning. |
|
Mrs. Blackburn. Thank you, Mr. Chairman. |
|
Ms. Yocom, I want to come to you. I thank you for being so |
|
persistent and consistent in coming to us. |
|
Let's go back to the formulary issue. In looking at the |
|
FMAP, I want to hear from you when you look at the per capita |
|
or the total taxable resources, what do you think is the better |
|
option and why would that option be your choice? |
|
Ms. Yocom. From GAO's perspective, total taxable resources |
|
are a much better indicator of a state's available resources to |
|
finance the program. I just looked at this yesterday and there |
|
is about a 40 percent difference between the total taxable |
|
revenue and per capita income. So, 40 percent more additional |
|
spending is included within total taxable resources. And what |
|
happens is you have inequities across states in terms of what |
|
is reflected in the per capita income. States with a lot of |
|
people who work in one location and live in another, those |
|
kinds of things don't always get counted in the correct manner. |
|
Corporate gains and corporate taxes and then also high-energy |
|
states are other areas where the allocations aren't necessarily |
|
consistent. |
|
Mrs. Blackburn. OK, thank you for that. |
|
Let's talk about additional assistance that is sometimes |
|
available during an economic downturn and how that affects a |
|
state and how would that affect the states' incentives and how |
|
should we approach that. Because you want to be helpful but you |
|
don't want to have a system where they are dependent on this |
|
and just say oh, well. |
|
Ms. Yocom. Right. Well, states, in the 50-year history of |
|
the program, have always been in a bind during an economic |
|
downturn. People lose their jobs and their children, at least, |
|
and sometimes the adults, qualify for Medicaid. So you have an |
|
increase in Medicaid enrollment. And then along with that, tax |
|
revenues go down because it is a recession or a downturn. So, |
|
they have more people in the program and less money to pay for |
|
it. |
|
One of the advantages of a federal-state partnership is the |
|
federal government offering that balancing of those |
|
circumstances. |
|
Mrs. Blackburn. Let me ask you this. States that have |
|
accessed those funds, once the economy recovers, how quickly do |
|
they go about removing those individuals from the rolls? |
|
Ms. Yocom. It honestly varies a great deal. |
|
Mrs. Blackburn. OK. |
|
Ms. Yocom. And probably the hardest part of any kind of |
|
automatic assessment, adjustment like we are talking about, is |
|
when to turn off the assistance. Unemployment tends to be a |
|
lagging economic indicator so recovery can be slow. |
|
Mrs. Blackburn. All right, thank you for that. |
|
Ms. Schwartz, MACPAC has publicly supported the extension |
|
of the Enhanced Federal Matching Rate for Medicaid Eligibility |
|
Systems. Talk to me about the criteria that MACPAC uses for |
|
assessing whether to support an enhanced federal matching rate, |
|
just if you will quickly articulate that. |
|
Ms. Schwartz. Sure. In our letter commenting on that role, |
|
the criteria that compelled the commission in that instance to |
|
be supportive of the continued Enhanced FMAP were that the FMAP |
|
rate would be tied to concrete performance standards by the |
|
state and that these would improve the eligibility in the |
|
enrollment process, both from the perspective of the |
|
beneficiary and from program administrators who enhance data |
|
collection reporting and improve administrative capacity. And I |
|
think this enhanced rate also recognizes that Congress already |
|
approves enhanced match for mechanized systems and increasingly |
|
enrollment in eligibility processes, which would have once been |
|
largely administered face-to-face are no mechanized systems as |
|
well. So, those are the criteria used in that respect. |
|
Mrs. Blackburn. OK, thank you. I yield back. |
|
Mr. Pitts. The chair thanks the gentlelady and now |
|
recognizes the gentlelady from California, Ms. Matsui, for 5 |
|
minutes for questions. |
|
Ms. Matsui. Thank you, Mr. Chairman. |
|
Dr. Schwartz, I want to ask you about long-term and FMAP |
|
enhancements. The majority of seniors and people with |
|
disabilities want to remain at home to receive long-term |
|
services and supports, instead of going to a nursing home or an |
|
institution. Research demonstrates that this is more cost- |
|
effective. Yet, despite some success, many states lag behind in |
|
providing services at home because of Medicaid institution |
|
bias, where nursing home coverage is mandatory and home and |
|
community-based services are optional. |
|
Congress has passed several FMAP incentives to fix this |
|
problem, such as Community First Choice, the Balancing |
|
Incentive Program, and Money Follows the Person. Some have |
|
expired or will expire soon. I believe this committee should |
|
absolutely be having a conversation on reauthorization of these |
|
programs, which are overwhelmingly bipartisan. |
|
Dr. Schwartz, how well have those FMAP incentives worked? |
|
Ms. Schwartz. The Balancing Incentives Program was focused |
|
on targeting states that spent less than half of their long- |
|
term services and supports money on home and community-based |
|
services to help them make this shift from facilities |
|
community-based services. And states were invited to submit a |
|
budget and a plan for how they would do that. |
|
Of the 17 states that had participated in the first |
|
quarter, 11 exceeded that threshold. It is not possible for me |
|
to say whether it was the Enhanced FMAP that did that or some |
|
of the other supports that were provided as part of that |
|
program and states may continue to make progress toward their |
|
goals, even though the enhanced match has expired. |
|
In addition, stats have many other avenues by which they |
|
can shift services from a nursing facility to home and |
|
community-based services, both through state plan options and |
|
through waiver services. |
|
So, there are a variety of approaches that states can take |
|
and tailor to their specific needs and populations. |
|
Ms. Matsui. Can you comment on some of the organizations |
|
you would have to improve upon the incentives that we have to |
|
states to show that people can remain at home? |
|
Ms. Schwartz. MACPAC has not made a recommendation on |
|
creating a financial incentive to do that. We closely monitor |
|
what is going on in the long-term services and support state |
|
space but are encouraged by the shift to home and community- |
|
based services, which is both fiscally promising and also |
|
responsive to patient and family needs and desires. |
|
And one area where we are closely monitoring is the move to |
|
manage long-term services supports, which we are still learning |
|
about and we still are looking forward to some of the outcome |
|
measures about how that shift is going. |
|
Ms. Matsui. Thank you. I think you will realize how much |
|
interest there is in long-term care delivery, especially in a |
|
population that is growing and the families willing to in some |
|
way accede to the wishes of their parents. |
|
And so I think it is something where long-term delivery in |
|
this country, which Medicaid, the single largest payer, |
|
deserves a lot of our attention on this committee. |
|
Ms. Yocom, the committee has been very interested in GAO's |
|
proposal for automatic trigger. I think the idea of making FMAP |
|
even more responsive to states leads to a worthwhile |
|
discussion. I have a couple of additional questions to clarify |
|
this proposal. |
|
Why does a prototype formula focus on providing increased |
|
assistance during national economic downturns and not regional |
|
downturns? |
|
Ms. Yocom. Sure. The big issue with the regional downturn |
|
is it is not always regional. For example, if there is a |
|
recession that is association with energy, it can be spread |
|
across states, all the way across the country from Alaska to |
|
Texas, to Wyoming, and so on. And it is much more difficult to |
|
think about targeting a small group of states like that. So, |
|
our focus has been more on the national downturn. |
|
Ms. Matsui. Could we look at that a little bit more? |
|
Because I am thinking about our recent recession which was |
|
caused by the housing crisis. And there are certain areas of |
|
the country that were really hit harder than others. I think if |
|
you look on a map, you can kind of identify those areas. I am |
|
just saying that I think that is something to look at because I |
|
think if you wait to look at the national model, we will miss |
|
those really hard-hit regional areas. |
|
Ms. Yocom. Yes. |
|
Ms. Matsui. Something to consider with any discussion are |
|
the winners and losers of the policy, whether some states may |
|
benefit more on their policy than others. And I think, to a |
|
certain degree, we are talking about this when I talk about the |
|
regional downturn. |
|
So, what type of variation can be seen with the enactment |
|
of your emergency trigger proposal? |
|
Ms. Yocom. Well, there is a lot of variation. That is maybe |
|
the bad news from your perspective. The good news is the |
|
variation is very dependent on which states are affected by the |
|
downturn and it changes from recession to recession. |
|
In our work, we looked at four different downturns and the |
|
differing effects that happened on states. So, while one state |
|
may not get an additional FMAP, it would be because they didn't |
|
need it that particular time. |
|
Ms. Matsui. OK, thank you very much. |
|
Mr. Pitts. The chair thanks the gentlelady and now |
|
recognizes the vice chair of the subcommittee, Mr. Guthrie, for |
|
5 minutes for questions. |
|
Mr. Guthrie. Thank you. Thank you, Chairman, for calling |
|
this hearing. I know it is a very complex financing system we |
|
have. And I think a couple of things, one of its states it |
|
appears, you know what Mr. Hagg you have found is just improper |
|
billing. Another thing is just trying to find ways to maximize |
|
the way the FMAP formula works in ways that probably we didn't |
|
intend but it is not necessarily wrong on their point. |
|
But in your testimony, you did note that provider taxes, |
|
intergovernmental transfers and upper payment limits have the |
|
effect of distorting the FMAP rates and ``undermine the |
|
federal-state partnership in financing health care.'' |
|
While this is a long-standing concern of OIG, can you |
|
comment on what degree you think this distortion may have |
|
increased in recent years, given the budget challenges states |
|
are facing? |
|
Mr. Hagg. Well, we haven't studied the extent of which |
|
those mechanisms have increased in recent years. So, I don't |
|
know definitively. I think it is safe to say, at least, |
|
generally speaking what we see specifically involving health |
|
care provider taxes, I think those have been on the rise in |
|
recent years. |
|
Mr. Guthrie. And Ms. Yocom, do you have any comments that |
|
shed light on that question? |
|
Ms. Yocom. I can't give you a specific number. I do know |
|
that our work has shown an increase in provider taxes and an |
|
increase in supplemental payments and these can be used to have |
|
an influence on the amount of federal money that is received. |
|
Mr. Guthrie. Thank you for that. And then Ms. Yocom, I have |
|
a question for you as well. |
|
I would be interested to learn more about the assistance |
|
distributed under GAO's prototype formula. Am I correct that |
|
this prototype formula would have been less costly than the |
|
assistance provided through the Recovery Act? |
|
Ms. Yocom. Yes, you are. We tested it over several |
|
recessions and it ranged from providing $9 billion in |
|
assistance to about $36 billion, which was under the big |
|
recession. |
|
The reality is, though, that the Recovery Act was |
|
attempting to do more than make Medicaid whole. They used |
|
Medicaid as a vehicle to provide additional state support. |
|
Mr. Guthrie. OK. And am I correct in understanding that if |
|
Congress were to implement the prototype formula compared to |
|
current law, not the Recovery Act but the current law, this |
|
change would need to be offset, since it would increase federal |
|
outlays during a downturn? |
|
Ms. Yocom. I believe so. You would really have to work with |
|
CBO on that. They are the experts. |
|
Mr. Guthrie. OK, it appears to be. |
|
And Dr. Schwartz, when MEDPAC presents this committee with |
|
recommended changes to the Medicare program, it routinely also |
|
provides the committee with recommended policies to adopt to |
|
offset the changes. Unfortunately, MACPAC does not offer ideas |
|
about ways to offset Medicaid or CHIP changes. If MACPAC wants |
|
us to be able to move forward on your recommendations, why |
|
doesn't MACPAC mirror MEDPAC's practice? |
|
Ms. Schwartz. To that point, I would first note that a |
|
number of our recommendations have had no budgetary impact and |
|
in that case, a no-saver would be needed. |
|
We are now engaging, as part of our work on children's |
|
coverage, in particular, and the work that we would be doing |
|
for you on financing, looking to see what kinds of saving |
|
options might be out there. And we do always try to work with |
|
CBO in understanding the fiscal effects of the recommendations. |
|
And that has certainly affected the commission's decision- |
|
making when considering different options. |
|
Mr. Guthrie. All right, thank you. |
|
And I will just close with this statement. I was in the |
|
state government in Kentucky and we do a biannual budget. So, |
|
just general revenue budget, my first one was the year 2000, |
|
so, for 2001 and 2002. And our biannual budget in Kentucky is |
|
about $13 billion. That is not exact but it is close. And since |
|
then, talking about the strains on state budgets, since then I |
|
know we have cut universities, we have had a lot of strain. And |
|
I think last year's biannual budget was close to $19 billion. |
|
So, it has gone up a third in a decade or whatever. And so it |
|
has been consumed, a large part, there is other things, drivers |
|
of the debt, but a large part of it is Medicaid. And so as |
|
these states are looking, I think, for opportunities to |
|
maximize FMAP and to make their budgets balance, it is just |
|
Medicaid is continuing to consume more and more of our federal |
|
deficit and more and more of what states do. |
|
So, this is helpful for us so we can get a handle on this. |
|
If we don't there is going to be no discretionary money for |
|
states to spend in educating our children and it is going to be |
|
difficult for us to ever get our budget balanced, if we don't |
|
do so. |
|
So, your information today has been very helpful and I |
|
appreciate that very much. I yield back. |
|
Mr. Pitts. The chairman thanks the gentleman. And now I |
|
will recognize the gentleman from New Mexico, Mr. Luja AE1n, |
|
for 5 minutes for questions. |
|
Mr. Luja AE1n. Mr. Chairman, thank you very much. |
|
As we all know, Medicaid is a lifeline to so many but as I |
|
noted in my opening statement, New Mexico's Behavioral Health |
|
System is in crisis as well. I described the upheaval that has |
|
resulted in the Susana Martinez administration going after so |
|
many of these providers. And as I said today, there were just |
|
on Monday ten more of those providers that had allegations |
|
against them of fraud were exonerated. And contractors were |
|
brought in from outside of the state to take over a system. The |
|
current infrastructure was dismantled and we need a lot of |
|
support there. |
|
But with that being said, during the New Mexico |
|
delegation's many conversations with CMS on the crisis and its |
|
impact in New Mexico, we, the delegation, asked CMS to provide |
|
us with data that CMS was receiving from the State of New |
|
Mexico that they are collecting from them. We hope that the |
|
data could provide us with something insightful, with a better |
|
look at what was happening on the ground and not happening on |
|
the ground. Unfortunately, after months and months of delay, |
|
the response that the delegation from New Mexico received from |
|
CMS was that CMS admitted that the stated-provided data had, |
|
and I quote, ``significant limitations.'' This left CMS largely |
|
unable to determine which, ``areas and populations may be |
|
experiencing decreases in utilization.'' |
|
So, the data being collected right now, at least from the |
|
State of New Mexico, is not able to help anyone make any |
|
decisions. So, without access to meaningful data, how is it |
|
possible for the people of New Mexico or us here to make |
|
decisions and how can people hold policymakers accountable? |
|
Without access to meaningful data, no one can know if |
|
enough is being done to ensure that the most vulnerable are |
|
protected and without access to meaningful data, we can't |
|
determine how best to strengthen the program for the most |
|
vulnerable. That is why I am interested in determining how we |
|
can use FMAP to help states build out and prioritize behavioral |
|
health infrastructure, data, and access. |
|
So, Dr. Schwartz, if we want states to build and maintain |
|
strong behavioral health systems, are there ways we can use |
|
FMAP to do so? |
|
Ms. Schwartz. I would say first to the point of data, the |
|
issue of data is one that MACPAC has consistently noted and |
|
noted concern about the need for data for many purposes, for |
|
program integrity purposes, for the purposes of improving value |
|
and monitoring quality and improving quality. And this is an |
|
area where CMS has been working to change its system to |
|
something called the T-MSIS, the Transformed MSIS, which has |
|
been going much more slowly than anyone would have anticipated. |
|
There are many things that states could do to strengthen |
|
behavioral health systems. Of course, states might prefer |
|
Enhanced FMAP. States have many options in the types of |
|
benefits that they can provide in behavioral health and states |
|
are, there is wide variation in how they do that. They have a |
|
wide variation in how they structure their systems in terms of |
|
the providers that they have, their use of managed care for |
|
behavioral health. So, a whole range of strategies. |
|
MACPAC's work at the moment is trying to look at whether |
|
there are barriers and whether those barriers are in the |
|
practice environment, the state environment, or the federal |
|
environment for integration of behavioral health services with |
|
physical health services. Because for many of these |
|
populations, regular contact with a physical health provider is |
|
their major point of contact with the health system. |
|
Mr. Luja AE1n. And so you answered the next question that I |
|
was going to pose, which was if you could speak how Congress |
|
has used FMAP to incentivize states to prioritize health care |
|
delivery systems. And one of the areas that it seems that |
|
Enhanced FMAP has worked is the long-standing family planning |
|
enhanced match, which appears to have drastically improved |
|
Medicaid access to families. |
|
But with that being said, the bill that I am working on |
|
provides an Enhanced FMAP to states that prioritize investments |
|
and infrastructure access and data collection. I would be |
|
curious to hear what types of suggestions you have about the |
|
interventions that are important that would maybe be most |
|
successful to help this program. |
|
Ms. Schwartz. I would be happy to take a look at that for |
|
you and get back to you on the details of it. There may be some |
|
technical assistance that we can provide in that regard. |
|
Mr. Luja AE1n. I appreciate that Dr. Schwartz. |
|
And Mr. Chairman, thank you so much for this important |
|
hearing today and I yield back the balance of my time. |
|
Mr. Pitts. The chair thanks the gentleman. I know recognize |
|
the gentleman from Illinois, Mr. Shimkus, for 5 minutes for |
|
questions. |
|
Mr. Shimkus. Thank you, Mr. Chairman. If Graham would put |
|
the slide up. |
|
Every time I deal with a Medicaid debate, of course, Ms. |
|
Yocom, you know you have seen this numerous times, the red is |
|
what the CBO would say is the mandatory spending, the blue is |
|
the discretionary budget. When we have a budget fight and there |
|
is a threatened shutdown, it is on the blue that the fight is |
|
about. So, this is a simple question but it is one that we, |
|
here out in the district, we use that term mandatory or we use |
|
the word for portions of the red, not all of them, as |
|
entitlement spending. |
|
Anyone want to comment on those two words as good words or |
|
bad words to use? Ms. Mitchell. What should they be called? Are |
|
they good? |
|
Ms. Mitchell. I don't know. I don't know that I am |
|
qualified to answer that. |
|
Mr. Shimkus. OK. |
|
Ms. Mitchell. But entitlement, meaning that Medicaid is an |
|
entitlement, meaning that both the states are entitled to |
|
Medicaid funding and individuals are entitled to Medicaid |
|
coverage, so that means there is no cap and states cannot put |
|
on---- |
|
Mr. Shimkus. And that makes it mandatory because they are |
|
entitled to the coverage. |
|
Ms. Mitchell. Yes. |
|
Mr. Shimkus. Dr. Schwartz? |
|
Ms. Schwartz. Yes, all these---- |
|
Mr. Shimkus. These are important. It might sound like a |
|
goofy talk but it is really out there. People get confused. And |
|
if we are trying to deal with what Mr. Guthrie was talking |
|
about, the national debt, part of the national debt is our |
|
promises to pay entitled people with mandatory spending. |
|
Ms. Schwartz. You know the labels are all extremely value- |
|
laden but you point out correctly that when states spend money |
|
on these services that are authorized within the statute, |
|
populations who are entitled to those services and deemed |
|
eligible by those states, those funds flow through and the |
|
federal share is mandatory. It is not subject to an |
|
appropriation. |
|
Mr. Shimkus. Great, thank you. |
|
Ms. Yocom, did I fairly, accurately talk through that? |
|
Ms. Yocom. Yes, I think that your statement is accurate. |
|
Mr. Shimkus. Mr. Hagg? |
|
Mr. Hagg. I am not sure I would have anything new to add. |
|
Obviously, Medicaid is a very important program. For the people |
|
who receive their health insurance through it, it is a |
|
tremendously important program. |
|
Mr. Shimkus. Right but this is a 2014 pie chart of $3.5 |
|
trillion of federal spending and then, again, the discretionary |
|
portion is anywhere between $1 trillion and $1.2 trillion and |
|
the rest is, as you have identified entitled or mandatory |
|
payment to meet the entitlement. So, I appreciate that. |
|
[Slide shown.] |
|
|
|
|
|
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] |
|
|
|
|
|
Mr. Shimkus. We had a discussion. In fact, Mr. Lujan also |
|
mentioned this 90 percent enhanced family planning match that |
|
we discussed based upon it. |
|
Mr. Hagg, does the OIG have the capacity to continually |
|
audit all states' claimed federal matching for family planning |
|
services? |
|
Mr. Hagg. No, we don't have that capacity. |
|
Mr. Shimkus. Given that the Medicaid program is a shared |
|
federal and state responsibility and given OIG's limited |
|
resources, is it fair to say that states have a responsibility |
|
to do audits and prioritize oversight where there are known |
|
vulnerabilities? |
|
Mr. Hagg. Yes, I think that is fair to say. You know it |
|
starts with the states. The states have the responsibility to |
|
make sure that the expenditures they claim are accurate, in the |
|
case of family planning or other enhanced FMAP categories that |
|
the correct expenditures are in those categories. |
|
Mr. Shimkus. Great, thank you. |
|
And Dr. Schwartz, in your testimony, you noted one concern |
|
with the FMAP is that states have an incentive to broaden |
|
Medicaid to include other state health functions, where |
|
possible, in order to draw down federal funds. Can you |
|
elaborate and give an example of what you mean? |
|
Ms. Schwartz. I think when state resources are tight, there |
|
are incentives to look for other sources of revenue, whether it |
|
is for school-based services, transportation, or public health |
|
services. |
|
From MACPAC's perspective, our focus has always been on |
|
looking for policies to make sure that the eligibility |
|
decisions are made correctly, that the services are provided |
|
to, enrollees are medically necessary and appropriate and the |
|
providers meet the federal and state participation |
|
requirements. |
|
Mr. Shimkus. So, states are dipping into Medicaid dollars |
|
for other services that may not be appropriate, based upon the |
|
definition of Medicaid. They are gaming the system. |
|
Ms. Schwartz. That is the distinction that I want to make. |
|
And I am sure that the gentleman from the OIG may speak to this |
|
as well. From MACPAC's perspective, when states claim federal |
|
match, those services must be legally matchable from legal |
|
sources of revenue, even if they are provided in different |
|
settings. |
|
Mr. Shimkus. And that is your recommendation. Your |
|
recommendation is that they follow that. |
|
Ms. Schwartz. Yes. |
|
Mr. Shimkus. OK, that is it. Thank you, Mr. Chairman. |
|
Mr. Pitts. The chair thanks the gentleman. I know recognize |
|
the gentlelady from Illinois, Ms. Schakowsky, for 5 minutes for |
|
questions. |
|
Ms. Schakowsky. Thank you. Thank you, Mr. Chairman. |
|
The importance of Medicaid just simply can't be overstated. |
|
I want to start with that because just yesterday the CDC |
|
released new data showing that states that have expanded |
|
Medicaid have an uninsured rate of ten percent for adults age |
|
18 to 64, probably still too many, but yet compared to an |
|
uninsured rate of 17.3 percent for non-expansion states. |
|
However, many states, including my home state of Illinois, |
|
received FMAP rates very close to the statutory minimum of 50 |
|
percent. In fact, Illinois receives an estimated 3.1 percent of |
|
annual FMAP funding that covers 4.8 percent of the nation's |
|
Medicaid beneficiaries. |
|
And I would like unanimous consent to enter into the record |
|
a document prepared by the Illinois Hospital Association which |
|
highlights the importance of Medicaid to Illinois. |
|
Mr. Pitts. Without objection, so ordered. |
|
Ms. Schakowsky. It is well-known that Medicaid payment |
|
rates are low, especially compared to the payment rates of |
|
Medicare and the private industry, private insurance. The need |
|
to adequate payments to Medicaid providers is incredibly |
|
important in providing stability in our healthcare system and |
|
ensuring access to providers for Medicaid beneficiaries. States |
|
have the flexibility of providing supplemental payments to |
|
providers and I believe this flexibility should be maintained. |
|
So, Ms. Schwartz, let me ask you. While some of the |
|
testimony today has focused on supplemental payments made to |
|
providers, I am more concerned about ensuring that providers |
|
receive adequate payments for services provided under Medicaid. |
|
Are underpayments to providers a systemic problem in the |
|
Medicaid program? |
|
Ms. Schwartz. I think that on the physician side, the |
|
literature has really consistently shown a relationship between |
|
fees and physician participation. And when fees are lower, |
|
physicians are less willing to participate and, therefore, the |
|
potential for access problems. The lower rate that Medicaid |
|
generally pays for a physician's services relative to Medicare |
|
is also well-documented and that was part of the thinking |
|
behind the primary care payment increase in 2013 and 2014. |
|
On the hospital side, it is significantly more complicated |
|
because states can pay hospitals through many different |
|
mechanisms, including their base payment rates, non-DSH |
|
supplemental payments, and DSH payments. |
|
The degree to which total payments to hospital in the |
|
aggregate varies considerably across states and we don't know a |
|
lot about hospital-specific payments. And for that reason, |
|
MACPAC has recommended 2 years ago and more recently in the DSH |
|
report that we released on February first that we need more |
|
data to better understand how hospitals are being paid. We |
|
recommended that the secretary collect and report hospital- |
|
specific data on all types of Medicaid payments that they |
|
receive and on the sources of the non-federal share so we can |
|
determine net Medicaid payment and we can help answer the kinds |
|
of questions that are you are raising. |
|
Ms. Schakowsky. I am sorry. What happened February first, |
|
did you say? |
|
Ms. Schwartz. On February first, MACPAC released a |
|
statutorily required report to look at Medicaid payments to |
|
Disproportionate Share Hospitals. |
|
Ms. Schakowsky. OK, thank you. |
|
States, including Illinois, use intergovernmental transfers |
|
or IGTs to legitimately, I believe, fund their Medicaid |
|
programs. Medicaid statute, since its inception, requires |
|
states to use state general funds to pay for 40 percent of |
|
their share of Medicaid funding. States are afforded |
|
flexibility to fund their portion and draw down the federal |
|
share. In addition, many states use provider assessments to |
|
ensure stability in their Medicaid programs. Without provider |
|
assessments, Illinois' Medicaid program would cover less than |
|
70 percent of the cost for Illinois hospitals to care for the |
|
state's most vulnerable population. |
|
So, Ms. Schwartz, is there a component of these legitimate |
|
payment mechanisms that--isn't it really the states and the |
|
providers that are willing to put up their share and shifts the |
|
burden really to them, a burden that they are willing to |
|
accept, which I see as a good thing? |
|
Ms. Schwartz. I guess just to build on what I said |
|
previously, states are allowed to use intergovernmental |
|
transfers. We know much less about those intergovernmental |
|
transfers than I think we would like to know and that is part |
|
of the rationale for our recommendation to collect more data on |
|
that. We have been relying on some work GAO did that is |
|
illustrative of the issue but not nearly as comprehensive that |
|
you would need to make a significant policy change in that |
|
area. |
|
Ms. Schakowsky. But isn't it sort of obvious that if the |
|
states' ability to creatively finance their Medicaid programs |
|
are further restricted, that it would led to cost them services |
|
and benefits for the beneficiaries? |
|
Ms. Schwartz. It is hard for me to predict how states would |
|
react. States may have other sources and I couldn't comment on |
|
the specific reaction that states would have to such a change. |
|
Ms. Schakowsky. And so you are looking more carefully into |
|
this. And when do we expect to know something? |
|
Ms. Schwartz. Well, I think legislation is needed for the |
|
Secretary to collect those data. |
|
Ms. Schakowsky. I yield back. |
|
Mr. Pitts. The chairman thanks the gentlelady. |
|
Ms. Schwartz. Excuse me. I am sorry, sir. |
|
Mr. Pitts. Yes. |
|
Ms. Schwartz. I just need to correct what I said. The |
|
Secretary doesn't need legislation but the Secretary has been |
|
reluctant to and, therefore, it might be wise on the part of |
|
the congress to actually direct the Secretary to do that. |
|
Mr. Pitts. The chair thanks the gentlelady. I now recognize |
|
the gentleman from Virginia, Mr. Griffith, for 5 minutes for |
|
questions. |
|
Mr. Griffith. Thank you very, Mr. Chairman. |
|
Ms. Yocom, I have tremendous appreciation for the work that |
|
GAO does to evaluate policies and advise the committee. |
|
However, I am concerned that the current that the current |
|
process for appointing commissioners for MACPAC may be |
|
fundamentally flawed. |
|
For example, the MACPAC statute explicitly allows for |
|
Medicaid directors to serve on the commission, however, there |
|
is not one single Medicaid director serving on the commission |
|
today but Medicaid is supposed to be a federal-state |
|
partnership. So, I ask, why hasn't GAO put someone on the |
|
commission who is actually running a Medicaid program today? |
|
Ms. Yocom. Sir, I know that the Comptroller General is |
|
working on a response to the committee's request and I would |
|
like to defer until that comes to you. |
|
Mr. Griffith. I appreciate that. |
|
And Dr. Schwartz, I have got to tell you, as an attorney, I |
|
am very troubled by an apparent conflict of interest from some |
|
of the commissioners. Having read Ms. Rosenbaum's reply to |
|
Chairman Upton and Pitts, I have to tell you it was |
|
unsatisfactory in my judgment. In my opinion, when you read |
|
that letter carefully, it is a clear conflict under legal |
|
ethical standards that the chairwoman, even though she wasn't |
|
chairwoman at the time, would sign onto a case adverse to the |
|
House of Representatives when she is a sitting MACPAC |
|
commissioner. It doesn't matter whether she was chair or not at |
|
the time. |
|
And when you look at her letter, not only is she an |
|
attorney, which is clear in the letter, but she goes on to |
|
state that this case that she got herself involved in is ``the |
|
focus of my life's work.'' It is so core to her that that is |
|
her number one concern. If that is not the appearance of |
|
impropriety or a conflict of interest in the standard legal |
|
definition, I, frankly, don't know what is. |
|
And then she goes on in her letter to say that but now that |
|
I am chairwoman, I am not going to do any more work on that |
|
case. Well, if she has a conflict now as a chairwoman which she |
|
feels means she shouldn't work on that case, she shouldn't have |
|
worked on that case in the first place. |
|
And the issue is not resolved on the conflict of interest |
|
issue but it is also not exclusively her problem. One of the |
|
current commissioners sits on the board of a nonprofit which is |
|
involved in legal advocacy and has been involved in at least |
|
one class action suit against a state Medicaid program. Now, I |
|
have got to tell you, I can't see how these are not conflicts |
|
of interest in the sense of I understand there is a financial |
|
conflict of interest people talk about. I am talking about a |
|
judgment conflict of interest. In the legal standards, as an |
|
attorney, one of them is not just that you have a direct |
|
conflict but that there is an appearance of impropriety. There |
|
is an appearance of impropriety. And I think that it ought to |
|
be of concern and you all ought to be disturbed at MACPAC that |
|
you didn't anticipate that this would be a problem for the |
|
public and for members of congress. |
|
We need, as Congress, we need objective recommendations for |
|
strengthening Medicaid and CHIP. Given the concerns that the |
|
committee leaders have raised, I hope you understand my worry |
|
that MACPAC recommendations will be viewed as somewhat tainted, |
|
that there may be some conflict in there and that we can't rely |
|
on that, as we ought to be able to, as credible or objective in |
|
all cases. |
|
Now you know I know folks are good people and I don't know |
|
Ms. Rosenbaum but when you look at her letter, this is my |
|
life's work. That is the sign of a good person. But in this |
|
case, there was a mistake made, an appearance of impropriety, |
|
and she shouldn't be doing both her life's work and filing |
|
briefs or amicus briefs in opposition to the United States |
|
House of Representatives. |
|
As members of this committee know, and as others who have |
|
followed me through the years know, it is not a new position |
|
for me to recommend that we change the way we do things and |
|
that perhaps these appointments ought to be made directly by |
|
Congress. I plan to introduce a bill that will make MACPAC |
|
directly appointed by both parties. It is not a partisan bill, |
|
in that sense. Both parties, majority and minority would get |
|
appointments, House and Senate would get appointments. And I |
|
believe that is a proper way for us to proceed going forward. |
|
I look forward to working with folks to try to make that |
|
better. If they don't like the way we have the numbers |
|
configured, that is obviously something that can be discussed. |
|
But as a legislative advisory panel, we need to know we are |
|
getting the right stuff and that people don't have conflicts so |
|
steeped in their own personality that they would write a letter |
|
back to us and, in defense, say, ``But this is my life's |
|
work.'' |
|
I yield back. |
|
Mr. Pitts. The chair thanks the gentleman and recognizes |
|
the gentlelady from California, Mrs. Capps, for 5 minutes for |
|
questions. |
|
Mrs. Capps. Thank you, Mr. Chairman, and thank you to the |
|
panelists for your testimony today. |
|
While I always appreciate the chance to talk about the |
|
importance of Medicaid and CHIP. To both families and |
|
communities, it is critical that any proposed changes do not |
|
undermine the program's important role in our health care |
|
safety net. Unfortunately, we continue to see plans from some |
|
of my colleagues to cap services or to block the program, both |
|
ideas that would not make health care more affordable but |
|
would, instead, leave some of those who need the program |
|
without it and shift the cost to states and localities. This |
|
would undermine the fundamental principles of the program and I |
|
cannot express enough how damaging that would be to patients |
|
and my constituents. But we can all agree that there are ways |
|
to make the program more responsive on the financial end. |
|
Studies show that when the current federal formula for FMAP |
|
uses per capita income as a proxy to reflect a state's |
|
financial resources and Medicaid needs, it is a poor proxy for |
|
both. This misrepresentation sustains significant funding |
|
disparities among states taxed by the federal government with |
|
serving the health needs of their low-income residents. And |
|
states like California that have relatively higher financial |
|
resources but also relatively higher poverty rates, are |
|
misunderstood as having lower Medicaid cost pressures than the |
|
already do. |
|
In fact, one study undertaken by California Common Sense, a |
|
nonpartisan research group in my state, found that by using a |
|
more accurate measure of poverty and need, California should be |
|
receiving a 15 percent higher FMAP rate. |
|
Dr. Mitchell, how does the current FMAP under-reimburse |
|
states like California who have higher Medicaid cost pressures |
|
than are reflected? |
|
Ms. Mitchell. Well, GAO has done a lot of work in this |
|
area but you know with the current formula, they are only |
|
looking at the per capita income. So, they are not taking into |
|
consideration the number of poor people in the state, the |
|
number of people eligible for Medicaid. None of those factors |
|
are taken into account. |
|
Mrs. Capps. Without this more accurate measure that looks |
|
at the financial--well, maybe I should just stop and say does |
|
GAO want to respond. |
|
Ms. Yocom. Ms. Mitchell is correct. Our work has shown one |
|
of the ways that it plays out is you can have two states with |
|
the same per capita incomes and the way it translates into the |
|
Medicaid program has a really different effect. For example, a |
|
state with a high number of disabled and elderly individuals is |
|
going to be struggling to finance their program more than a |
|
state that is primarily comprised of children and families. |
|
Mrs. Capps. OK, thank you. |
|
So, without this more accurate measure that looks at the |
|
financial resources and Medicaid needs of the state, states |
|
like mine, California, have worked with their health care |
|
providers to maintain a stable functioning safety net health |
|
care system. One way they have done so is through our state's |
|
provider fee, that is used to help pay for the non-federal |
|
share of their Medicaid program. |
|
Federal Medicaid law requires that provider assessments be |
|
broad-based and uniformly imposed and federal laws and |
|
regulations guard against the misuse of provider assessments by |
|
states that seek to receive higher federal matching rates than |
|
statutorily allowed. |
|
In California, the provider community is strongly |
|
supportive of the fee, even non-safety net providers. The fee |
|
has been approved by CMS and is used right. Money that comes |
|
from the state health care system goes right back into it, |
|
targeting the providers who provide the most under and |
|
uncompensated care. Over the years, however, we have heard |
|
rumblings against the program. To be clear, cutting provider |
|
fees would hurt all individuals in the state, not just working |
|
families. |
|
Before the California fee went into effect, a dozen safety |
|
net hospitals were about to close their doors, not because they |
|
didn't have patients to care for but because they couldn't |
|
afford to stay open. The provider fee has given them new life |
|
so that they are there in the community for both Medicaid |
|
patients but also any community member who needs care. |
|
And with that, Mr. Chairman, I yield back the balance of my |
|
time. |
|
Mr. Pitts. The chair thanks the gentlelady and now |
|
recognizes the gentleman from Missouri, Mr. Long, for 5 minutes |
|
for questions. |
|
Mr. Long. Thank you, Mr. Chairman. |
|
Ms. Yocom, why is it that the current FMAP formula isn't |
|
sufficient for dealing with economic downturns? |
|
Ms. Yocom. A lot of it has to do with the timing and the |
|
fact that, as Ms. Mitchell talked about, the data that are |
|
represented by the FMAP calculation, in addition to not be |
|
complete enough, are also old. So, when you are in a steady |
|
economic time or a time of growth, it doesn't cause a problem. |
|
It is during a downturn that the real effects take place |
|
because the FMAP is reflecting economic circumstances that were |
|
several years ago. |
|
Mr. Long. OK, have you assessed how well the prototype |
|
formula would have worked in these previous downturns? |
|
Ms. Yocom. We have. Our first effort to create a model like |
|
this addressed about 90 percent of recession-related costs. And |
|
where we found that it was lacking was for states that were |
|
slow to enter a downturn and slow to recover. And so then we |
|
adjusted the way that we end the assistance period, based on |
|
states' activities and, did some slight improvement. I don't |
|
think we calculated the percentage of cost coverage since then |
|
but we believe it is a pretty strong formula. |
|
Mr. Long. You believe it is what? |
|
Ms. Yocom. It is a pretty strong formula for assessing |
|
states with their financial needs. |
|
Mr. Long. OK, my next question here is for you or Dr. |
|
Schwartz, whoever wants to take it first. |
|
What type of other policy proposals have been proposed in |
|
the past replacing FMAP and improving financing to the Medicaid |
|
program? |
|
Ms. Yocom. What types of policies have been proposed? |
|
Mr. Long. Yes, what type of policy proposals have been |
|
proposed in the past for replacing the FMAP and improving |
|
financing in the Medicaid program? |
|
Ms. Yocom. There was, at one point, legislation looking at |
|
adjusting the FMAP during a downturn. I do not know how far it |
|
got in the statutory path. |
|
Mr. Long. Dr. Schwartz. |
|
Ms. Schwartz. MACPAC has just conducted an historical |
|
review of major reform proposals and we are working on cleaning |
|
that up so that we can share it with the members of the |
|
committee and your staffs. Some of the ideas that have been |
|
talked about over the past 20 to 30 years include block grants, |
|
as have been stated earlier, per capita caps, capped |
|
allotments. Those are some of the proposals that we will be |
|
looking at going forward but we will provide you an analysis of |
|
some of those ideas. |
|
Mr. Long. And how would those options change the incentives |
|
and disincentives facing states? |
|
Ms. Schwartz. Well, they differ from each other in how they |
|
are designed but, in general, they change the nature of the |
|
relationship between the federal government and the states in |
|
providing more fiscal discipline in limiting the resources |
|
either in total or based on the number of enrollees or other |
|
mechanisms of that type. |
|
Mr. Long. OK, so there would be incentives and |
|
disincentives for states. |
|
Ms. Schwartz. Yes. |
|
Mr. Long. OK, thank you all. I appreciate your testimony |
|
here today. With that, I yield back. |
|
Mr. Pitts. The chair thanks the gentleman. I now recognize |
|
the gentleman from New York, Mr. Engel, for 5 minutes for |
|
questions. |
|
Mr. Engel. Thank you very much, Mr. Chairman. |
|
Mr. Hagg, I just have a couple of quick questions for you, |
|
based on the issues you have raised regarding my home State of |
|
New York. In your testimony, you noted past issues regarding |
|
reimbursement for developmental centers and residential |
|
habilitation centers. And in both of these instances, it was |
|
clear that both our state and CMS made administrative errors |
|
that resulted in overpayments for these services and, in both |
|
instances, all parties involved, including the State of New |
|
York and CMS largely agreed with OIG's findings. Is that not |
|
correct? |
|
Mr. Hagg. Yes, I think that is correct. |
|
Mr. Engel. Yes. It is my understanding that, following this |
|
report, New York and CMS worked cooperatively to both fix the |
|
problem in the future, as well as agreed upon a financial |
|
settlement to resolve the issue. That is true as well. |
|
Mr. Hagg. That is correct, yes. Initially it was trying to |
|
fix the problem moving forward and then it required some audit |
|
work looking backwards to figure out the scope of the problem, |
|
the extent of the problem. And then yes, the state and CMS |
|
worked closely together to reach that settlement. Yes. |
|
Mr. Engel. Thank you. Your testimony today also included |
|
the results of many investigations and my reading of these |
|
reports would indicate that nearly all ended with cooperation |
|
between the states and CMS to resolve the issues at hand. Is |
|
that correct? |
|
Mr. Hagg. Well, are you talking about the audits involving |
|
some of the Enhanced FMAP claiming areas? |
|
Mr. Engel. Yes. |
|
Mr. Hagg. Yes, I think, I don't have a list in front of me |
|
but I would think most, if not all, of those audits, CMS |
|
concurred with the recommendations that we made. I think in a |
|
lot of cases, the states agreed with our findings and |
|
recommendations as well. So, yes, CMS, as the action official, |
|
would work with the states to help implement those |
|
recommendations. |
|
Mr. Engel. OK. And finally, would you agree that most |
|
investigations on issues similar to New York's are addressed in |
|
a generally cooperative manner that improves the program |
|
integrity in the long-run? |
|
Mr. Hagg. I am sorry. Could you repeat that again? |
|
Mr. Engel. That the investigations on issues similar to the |
|
ones we have in New York, as you pointed out New York wasn't |
|
the only state, that those issues are generally addressed in a |
|
cooperative manner that improves program integrity in the long- |
|
run? |
|
Mr. Hagg. Generally speaking, yes. If CMS agrees with the |
|
recommendations we make in the states then, yes, there is a |
|
cooperative effort to try to help the program moving forward. |
|
Sometimes there are disagreements where states disagree with |
|
the findings that we have, with the recommendations that we |
|
make. Sometimes CMS disagrees with us. But by and large, when |
|
there is agreement, yes, there is a cooperative effort to help |
|
improve the programs moving forward. |
|
Mr. Engel. All right. Well, thank you. I just wanted to get |
|
those clarifications on the record. OIG has done very good, in |
|
my opinion, to ensure that reimbursements in the Medicaid |
|
program remain accurate and certainly, OIG has raised issues in |
|
the past but it is clear that these issues are solvable and |
|
always nearly end with both long-term program improvement and |
|
amicable agreement between the federal and state government. |
|
So, I just wanted to get that on the record. |
|
Thank you, Mr. Chairman. I yield the remainder of my time. |
|
Mr. Pitts. The chair thanks the gentleman and now |
|
recognizes the gentleman from Florida, Mr. Bilirakis, for 5 |
|
minutes for questions. |
|
Mr. Bilirakis. Thank you, Mr. Chairman. I appreciate it |
|
very much. I want to thank the panel for their testimony. |
|
GAO has listed Medicaid as a high-risk program for more |
|
than a decade. I am sure that you know that. The IG's Office's |
|
2015 Top Management and Performance Challenge Report has |
|
Medicaid fraud, waste, and abuse listed in the number one spot. |
|
Mr. Hagg, this week the Energy and Commerce Committee sent |
|
a letter to the IG's office asking for additional information |
|
on Medicaid payments related to deceased beneficiaries and |
|
deceased providers. Do you know the size and scope of the |
|
problem, how much money is being wasted, there shouldn't be any |
|
money wasted as far as I am concerned, what services or |
|
payments are being made, and why life status cannot be |
|
determined in a timely or accurate way? |
|
And I think it should be pretty simple but if you can |
|
answer that question, I appreciate it. |
|
Mr. Hagg. Yes, I don't have an answer to the scope of the |
|
problem or the magnitude of the problem. |
|
Over the years, we have conducted various audits going back |
|
a number of years, where we would identify Medicaid payments |
|
that were made for people that were deceased. We currently have |
|
some ongoing work looking at a few different states, trying to |
|
determine the extent of the problem for those individual |
|
states. It wouldn't be a national look but it would for |
|
individual states determine the extent of which payments are |
|
made for people that are deceased. |
|
Mr. Bilirakis. Well, why wouldn't we look at all 50 states |
|
in this case? |
|
Mr. Hagg. That is a resource issue. It is a lot of data to |
|
crunch and review. And once you have things that look like |
|
errors, there is specific work that needs to be done to look |
|
behind to make sure that we are actually talking about someone |
|
who is deceased. So, it just requires a lot of resources. |
|
Mr. Bilirakis. Well, it is my understanding we have had |
|
spot checks before and it just hasn't done anything. Why not a |
|
comprehensive look at the problem? As far as I am concerned, it |
|
is a big issue. |
|
Mr. Hagg. Well, I don't disagree with you. And you would |
|
think it would be something that over time we would be able to |
|
get correct. |
|
Mr. Bilirakis. How do you engage with the states? |
|
Mr. Hagg. How do we engage with the states? |
|
Mr. Bilirakis. Yes. |
|
Mr. Hagg. Well, anytime---- |
|
Mr. Bilirakis. Get the information necessary for the |
|
analysis. |
|
Mr. Hagg. Well, just like all of our work, we try to look |
|
at areas that we believe are high-risk areas of |
|
vulnerabilities, whether it is across states or in specific |
|
states. We decide, once we see those vulnerabilities, to |
|
conduct audit work that would address those specific areas, |
|
those vulnerabilities. If we decide to audit a specific state, |
|
we obviously meet with the state and talk to them about the |
|
audit we are going to perform, the scope that it would entail, |
|
and the methods that we would use. And we work with the state |
|
to get the data we need to make determinations to fulfill our |
|
objectives. |
|
Mr. Bilirakis. How many states have you identified so far? |
|
Mr. Hagg. For payments for deceased beneficiaries? |
|
Mr. Bilirakis. Yes, and how much money is involved? |
|
Mr. Hagg. Well, currently, I don't know the extent of the |
|
errors. We have ongoing work in two or three states, one that |
|
work is completed. We can talk about our findings more. Right |
|
now, I don't have any findings to report because the work isn't |
|
completed. |
|
Going back 10 years or more, there would be audits |
|
conducted by us and other groups that would find Medicaid |
|
payments for deceased beneficiaries. I think the amounts would |
|
vary from a million or two million here or there to higher |
|
amounts like in twenty-five million or more. |
|
Mr. Bilirakis. That is outrageous as far as I am concerned. |
|
OK, well please keep me informed---- |
|
Mr. Hagg. We would be glad to do that. |
|
Mr. Bilirakis [continuing]. Because I need to follow up on |
|
this. |
|
Thank you very much. I yield back, Mr. Chairman. |
|
Mr. Pitts. The chair thanks the gentleman. I now recognize |
|
the gentleman from Indiana, Dr. Bucshon, for 5 minutes for |
|
questions. |
|
Mr. Bucshon. Thank you, Mr. Chairman. |
|
Medicaid is a critical program. I was a physician in my |
|
previous career. I am still a physician but now I am here. But |
|
in my view, it needs broad reform and we are talking about some |
|
aspects of the law today. |
|
In many states, having Medicaid does not guarantee access |
|
to health care, other than through the emergency room and that |
|
is true today as it has been for quite a while. As the costs |
|
continue to rise overall in health care, more stress will be |
|
put on this critical program. |
|
One of the failures of the ACA is addressing coverage and |
|
not addressing cost. And without honestly looking at some of |
|
the things that are driving the cost and solving those, we are |
|
going to continue to be talking about coverage when we are |
|
missing the boat because it doesn't guarantee access. |
|
Price transparency for the consumer in health care doesn't |
|
exist. Quality transparency is getting better. The combination |
|
of those two is the value that you get from a service. |
|
Looking at tort laws, antitrust and stark law reforms, and |
|
many other things to try to help decrease the costs in our |
|
health care system will be imperative to the other things that |
|
we look at structurally within the Medicaid program. |
|
And this question goes to Dr. Schwartz or Ms. Yocom. Has |
|
anyone looked at Medicaid recipients and their ability to find |
|
access to a primary care physician, other than through the |
|
emergency room? So, for example, you have a Medicaid |
|
population. Has anybody surveyed them and found out the |
|
percentage of them that can't find a primary care physician to |
|
take care of them? |
|
Ms. Schwartz. There are a number of different surveys that |
|
have been done to look at access for Medicaid beneficiaries. |
|
One is using the National Health Interview Survey and asking a |
|
number of questions about access. Unfortunately, using that |
|
survey, we can't get state estimates. So, some of the variables |
|
that would be important about how states design their programs, |
|
you can't tell. |
|
Another approach that has been taken more recently by a |
|
group of researchers at the University of Pennsylvania is to do |
|
what they call Secret Shopper and call and pose as a private |
|
insurance patient or Medicaid patient and to see what the |
|
access barriers are. And they do see some differentials. In |
|
that study, they were also looking at difference in fees and |
|
found that states that had higher fees in the Medicaid program |
|
did have fewer barriers to access. |
|
Ms. Yocom. There is another national survey. Again, we |
|
cannot get down at the state level, which shows that from the |
|
perspective of the beneficiaries Medicaid access is viewed as |
|
comparable to that of private insurance with regard to initial |
|
primary care. And the difficulties reported in obtaining care |
|
get higher when you are talking about specialty care or |
|
behavioral health services, in particular. |
|
Now, what we don't know is the frame of references of those |
|
individual respondents, if they were previously uninsured and |
|
being on Medicaid may make things easier. |
|
Mr. Bucshon. Yes, I understand the study but amongst the |
|
community that I represent, we hear all the time about |
|
difficulty finding physicians and we are hearing more about |
|
Medicare patients, finding access to primary care physicians |
|
because physician practices are closed to those populations, |
|
based on the low reimbursement rates. |
|
Mr. Hagg, when the state claim a higher federal matching |
|
rate than they are entitled, what is the process for the |
|
federal government to be made whole? |
|
Mr. Hagg. Well, specifically tied to the work that we |
|
performed, if the state agrees and CMS agrees, it could be a |
|
fairly quick process. And the next quarter, the state would |
|
return the funds. |
|
Mr. Bucshon. That is the question. So, the next quarter of |
|
the payment can be rectified? |
|
Mr. Hagg. If the state agrees that it is an overpayment. |
|
Now, if they disagree, there are certain appeal rights that |
|
they have that they can go through. Once those appeal rights |
|
are exhausted and it is still determined to be a legitimate |
|
overpayment, an overpayment that CMS agrees with, as the action |
|
official, CMS would issue a disallowance letter to the state. |
|
That may take several quarters to actually get the money back |
|
at that point, then. |
|
Mr. Bucshon. OK, great. And Ms. Yocom, obviously, there is |
|
a tradeoff between complexity and accuracy involved in |
|
alternative measures to determine and to allocate Medicaid |
|
funding to the states. Can you just briefly comment on that? |
|
Is there any not complex, accurate way to do this or is it |
|
just a balance? |
|
Ms. Yocom. Unfortunately, there probably isn't. There is a |
|
tradeoff, though, between how complex you want your formula to |
|
be versus how simple it is to implement. |
|
I think really, at the end of the day, it is a |
|
congressional policy decision of how important it is to be as |
|
equitable as possible across the states. |
|
Mr. Bucshon. Thank you. My time is up. I yield back. |
|
Mr. Pitts. The chair thanks the gentleman and now |
|
recognizes the gentleman from New York, Mr. Collins, for 5 |
|
minutes for questioning. |
|
Mr. Collins. Thank you, Mr. Chairman. |
|
Let me explain, perhaps, a problem I have and then we will |
|
ask a little input. I am from Buffalo, New York, Erie County, |
|
New York, one of the poorest cities in the United States of |
|
America and hence, one of the poorest counties, with a very |
|
high percentage of Medicaid. |
|
So, it is my understanding that there are about 13 states |
|
out of 50, New York being one, that forced the counties to pick |
|
up a large piece of the state's share. Now in 37 out of 50 |
|
states, the state picks up their share, the federal picks up |
|
their share, and that is it. And that reimbursement rate is |
|
dependent on the state income level, compared to the national |
|
average. |
|
In New York and I think 12 other states, though, the state |
|
forces a big piece, as much as half of that state share down to |
|
the 62 counties in New York. So, New York being considered a |
|
wealthy state because of New York City, Westchester County, we |
|
are at the lowest level. We are reimbursed 50 percent. But in a |
|
poor county, then, like Erie County, the largest upstate county |
|
in New York, that share comes back to the county. We are only |
|
getting 50 percent. Yes, Mississippi, which has the same |
|
relative income level, gets 74 percent. So, you can see where |
|
yes, it is a state issue, perhaps, but I believe this |
|
reimbursement was to protect, if you will, the taxpayers of the |
|
poor states. Well, think of Erie County as a state. We are a |
|
very poor county, yet we are only reimbursed at 50 percent |
|
because of that. |
|
So, my thought would be having a state like New York that |
|
is 62 counties that forces it back on the counties, we should |
|
have 62 different reimbursement rates that accept that Erie |
|
County is a very poor county. |
|
And to put it in perspective, the county, little county, |
|
well it is a big county, but our county share of Medicaid was |
|
give or take $120 million a year, $120 million. Our entire |
|
county property tax was only $110 million. One hundred percent |
|
of our county property tax would not even cover our Medicaid |
|
portion. So, we had to dip into our sales tax collections to |
|
cover that. And then everything else in our budget from |
|
highways to all other services, jails, was covered by sales |
|
tax. |
|
So, I think you can see the dilemma we have as being one of |
|
the states where the state is forcing substantial costs, what |
|
they call the state share but in New York it is state and |
|
county share, and that we are a poor county. |
|
So, I guess the question, I don't know, perhaps to Ms. |
|
Mitchell, I have to assume it wouldn't be that hard to have 62 |
|
reimbursement rates, one for each county in New York. The data |
|
is easily available, I would presume. I know it would take a |
|
bill in Congress to say for those states which push it back to |
|
the local level, we will look at each county as a separate |
|
entity and recalculate that rate. |
|
And I know that is different than what we have now, but |
|
that wouldn't be that difficult to do, would it? |
|
Ms. Mitchell. I believe it could be possible to do that and |
|
unfortunately, at this point, those sort of decisions are made |
|
on a state level. States have a lot of discretion in how they |
|
design their program and how they fund their Medicaid program. |
|
Mr. Collins. But if a state did like New York, though, you |
|
could then go back to the federal government and say here is |
|
New York State's program so, in this case, let us recalculate |
|
for the 62 counties. I know it would take an act of Congress to |
|
do that but I think you can sense my frustration, as the county |
|
executive of a very poor county, being treated like we were |
|
from Westchester County, or Suffolk County, or Nassau County |
|
but we weren't, you know home to the City of Buffalo, third |
|
poorest city in the United States. |
|
So, would anyone else want to comment on that? Have you |
|
heard this argument from others? I mean there are 12 or 13 |
|
other states that do likewise. A lot of people have no idea |
|
this even happens. |
|
So, with that, I guess I will yield back the balance of my |
|
time but my thought would be if you could get Congress to move, |
|
the first question would be how hard would it be? And I don't |
|
think it would be that hard to calculate 62 different rates for |
|
New York, just the press of a spreadsheet button and there you |
|
go. |
|
Thank you very much, Mr. Chairman. I yield back. |
|
Mr. Pitts. The chair thanks the gentleman. I now recognize |
|
the gentlelady from Indiana, Mrs. Brooks, for 5 minutes for |
|
questions. |
|
Mrs. Brooks. Thank you, Mr. Chairman and thank you to the |
|
witnesses for your testimony. |
|
I want to commend, actually, my home State of Indiana for |
|
taking the lead in developing a groundbreaking approach in what |
|
is known as Healthy Indiana Plan, HIP 2.0. And it is an |
|
innovative, consumer-drive, health insurance program, as you |
|
know, designed to empower members to take personal |
|
responsibility for the health care decisions. And just as HIP |
|
2.0 encourages individuals to take responsibility, FMAP should |
|
encourage states to take responsibility of their financial |
|
health of the state Medicaid program. |
|
I would like to just talk about, because I think this is an |
|
important discussion, on how we maximize the federal dollars to |
|
provide for the best health outcomes for our nation's most |
|
vulnerable populations. And Ms. Schwartz, last Congress, I |
|
joined a bipartisan group of colleagues from the Women's Caucus |
|
to urge the renewal of CHIP. And moving forward, I want to |
|
ensure that we continue to provide care for those roughly 8 |
|
million children and pregnant women around the country, |
|
including roughly 84,000 children in Indiana. |
|
MACRA extended CHIP through the end of next September and |
|
the ACA increased CHIP's already enhanced FMAP by 23 percent. |
|
So, under MACRA, the federal government is paying, as you said, |
|
all the costs for CHIP in 12 states and paying 90 percent of |
|
the costs in an additional 20 states. |
|
So, the last time that the MACPAC commented on CHIP, there |
|
was a 2-year extension. And now that there is a more in-depth |
|
examination, I hope the commission is examining as to what |
|
degree a lack of a state contribution may affect the state |
|
incentives to ensure that Medicaid payments are appropriate and |
|
accurate. Can you comment on that? |
|
Ms. Schwartz. Certainly. The commission has a very |
|
aggressive work plan and is very focused and has committed to |
|
having a package of recommendations for Congress by the end of |
|
this calendar year, so that when Congress turns its attention |
|
again to funding for CHIP in the next Congress, that MACPAC's |
|
recommendations will be available. We are looking at many |
|
different aspects of the program, benefits, affordability, |
|
state administration and financing. And all of these will fold |
|
into those recommendations. You can see that that will be on |
|
the agenda, consume a considerable amount of the commission's |
|
time at every meeting over the course of this year. |
|
Mrs. Brooks. And is MACPAC evaluating incentives in CHIP's |
|
current program financing? |
|
Ms. Schwartz. Yes. |
|
Mrs. Brooks. And what, if any actions, has CMS taken to |
|
ensure the accuracy and the appropriateness of federal and |
|
state payments? |
|
Ms. Schwartz. I can't speak to what CMS' actions have been |
|
in this area. I can check into that and get back to you. |
|
Mrs. Brooks. OK, thank you. |
|
Mr. Hagg, the list of top management challenges for HHS |
|
identified protecting the Medicaid program from waste, fraud, |
|
and abuse as the number one challenge. When do you expect OIG |
|
report of the findings on this issue will be made public and |
|
can you talk about will your analysis review whether |
|
individuals whose medical services were financed at the |
|
enhanced matching level were actually eligible under the |
|
statute? And you talked a bit about that in your testimony. Can |
|
you expand on that? |
|
Mr. Hagg. Well, yes, a few different things. One, the list |
|
of top management challenges is really to highlight for the |
|
Department and others, external parties, the areas that we |
|
believe have large vulnerabilities. It doesn't tie to a |
|
specific report that we would put out to say specific problems |
|
have been solved or not. We have a body of work in Medicaid |
|
covering a lot of different areas and the results that we find |
|
leads us to the conclusion that Medicaid is a high-risk area. |
|
So, that is one thing. |
|
As far as some of the Enhanced FMAP rate categories, the |
|
one specifically you are talking about for the newly eligible |
|
population, we have some work ongoing. It is two different |
|
tracts, really. The first is some audit work that my team is |
|
doing. It is focused on states and the actions they are taking |
|
and claiming. The second tract is being done by our Office of |
|
Evaluations and Inspections. They are looking at CMS' |
|
oversights and their responsibilities and the action that CMS |
|
is taking. |
|
We anticipate that work being done sometime later this |
|
year. For the audit work as early as, well, probably not before |
|
the end of this calendar year. For the work that focuses on |
|
CMS, probably no earlier than maybe late summer. |
|
Mrs. Brooks. Is there a report that those of us who are |
|
working on Congressman Guthrie's Medicaid Task Force Reform |
|
efforts, is there a report that you can point to where we can |
|
dig in on the waste, fraud, and abuse recommendations that OIG |
|
has made? |
|
Mr. Hagg. Yes. Well, one, you have seen the top management |
|
challenges. That will lay out some of the things that we found. |
|
We have a semi-annual report that we put out, obviously, that |
|
highlights some of the areas of the bigger issues that have |
|
been identified. |
|
We have a compendium of unimplemented recommendations that |
|
talk about specific things that we think can still be done to |
|
help improve the program. And then beyond that, I would be glad |
|
to try to provide some of reports involving some of the bigger |
|
impact or higher risk areas that we have identified issues. |
|
Mrs. Brooks. Thank you. Thank you all for your work. I |
|
yield back. |
|
Mr. Pitts. The chair thanks the gentlelady. That concludes |
|
the questions of members present. |
|
There will be follow-up questions that we will send. We |
|
will send those to you in writing. We ask that you please |
|
respond promptly. |
|
Mr. Schrader. |
|
Mr. Schrader. Thank you, Mr. Chairman. I just briefly want |
|
to recognize that Medicaid basically insures almost 40 percent |
|
of the children in the United States of America. So, the impact |
|
of Medicaid on children should not be far from our minds. We |
|
have heard a lot of testimony today to that effect. |
|
So, I would like to ask unanimous consent to submit a |
|
statement from the American Academy of Pediatrics for the |
|
record, sir. |
|
Mr. Pitts. Without objection, so ordered. |
|
Mr. Schrader. Could I make just one final comment? |
|
Mr. Pitts. Yes, sir. |
|
Mr. Schrader. Just to keep the hearing in perspective, I |
|
appreciate the hearing. It is very timely, very important. At |
|
this point in time, it is pretty clear that there has been an |
|
uneven economic recovery. The good vice chair alluded to the |
|
fact that Medicare enrollments have increased over the last few |
|
years and I think that is indicative of the fact that a lot of |
|
folks are struggling to keep up, despite the fact that |
|
unemployment is way down and we are getting back our mojo, I |
|
think, as a country, but it is uneven at best. |
|
So, Medicaid provides I think a very important role. I |
|
would also like to point out that despite the complexity and |
|
although we have heard a lot about some of the unclear rules |
|
maybe from CMS in how the Medicaid money should be |
|
administered. And OIG and GAO have done a good job, I think, in |
|
pointing out some of the potential problems with |
|
interpretations program, no one has done anything wrong. |
|
So, at the end of the day, I would just like to point out |
|
that as far as a government program goes, Medicaid has the |
|
lowest improper payment rates of any federal health program. |
|
So, let's keep it in perspective and talk about what we need to |
|
be doing. |
|
Last comment, sir, thank you for your indulgence, is that |
|
the real answer to driving the cost down is, again, quality- |
|
based reimbursement. That is how you get the biggest bang for |
|
the buck without hurting the people that need the program the |
|
most. |
|
So, I am hoping that we have that opportunity to talk about |
|
this and some of the other ideas that come out of this hearing. |
|
And I really appreciate the fact that we have had this hearing. |
|
I yield back, Mr. Chairman. |
|
Mr. Pitts. The chair thanks the gentleman. Does the |
|
gentleman from Massachusetts seek recognition? |
|
Mr. Kennedy. Yes, if I may. |
|
Mr. Pitts. The gentleman is recognized for 5 minutes for |
|
questioning. |
|
Mr. Kennedy. Thank God. I apologize to all that were |
|
waiting and letting me catch my breath. |
|
Chairman, thank you for holding the hearing. To our |
|
witnesses, thank you for being here. Thank you for your |
|
testimony. |
|
Mr. Hagg, I wanted to direct the first question at you sir, |
|
if I may. One report that OIG has highlighted was a review of |
|
Medicaid claim adjustments in Massachusetts between 2008 and |
|
2010. I wanted to take a moment with you to discuss the report. |
|
The main finding, as I understand of the report was that our |
|
state over claimed federal revenue around the time of the |
|
American Recovery and Reinvestment Act. |
|
So, to start, the Recovery and Reinvestment Act was |
|
implemented in 2009. Is it true that nearly at the same time |
|
the Commonwealth implemented a new Medicaid management |
|
information system around that as well? |
|
Mr. Hagg. I believe that is correct. |
|
Mr. Kennedy. And so is it correct that after OIG's findings |
|
were raised that the Commonwealth agreed to address the issues, |
|
so long as CMS agreed with OIG's interpretation? |
|
Mr. Hagg. I would have to go back and look at the report. |
|
At this point, I am not sure I remember specifically exactly |
|
what the state comments were on our findings. |
|
Mr. Kennedy. OK. So, if I jogged the memory, and said that |
|
if OIG reported the Commonwealth overcharged by $106 million, |
|
does that strike you as---- |
|
Mr. Hagg. Yes, those were our findings. I just don't recall |
|
what Massachusetts' reaction was to those findings. |
|
Mr. Kennedy. So my understanding, sir, is that under OIG's |
|
interpretation on the other end of the ARA period, |
|
Massachusetts would have been undercharged by $108 million. |
|
Does that part ring a bell? |
|
Mr. Hagg. Well, I don't know that our audit period looked |
|
through that far. I don't think it covered that much. We |
|
focused on a specific period of time and the adjustments the |
|
state made during that time period. |
|
If the state believed that at the end of the period, the |
|
opposite effect would occur, then certainly, CMS, as the action |
|
official, would work with the state to take that into |
|
consideration and correct it. |
|
Mr. Kennedy. I appreciate that. I think the issue was, |
|
looking at one time period, the state had overcharged the |
|
federal government $106 million but looking at another time |
|
period, was in fact overcharged by $108 million. And you are |
|
saying you don't recall it but would look. |
|
Mr. Hagg. Well, again, CMS is going to be the action |
|
official on this. I am pretty sure that CMS concurred with our |
|
findings and recommendations. |
|
Now, without looking at that specific period that you are |
|
talking about or the state is talking about with an under |
|
claim, I really don't have the answer to that, whether that is |
|
accurate or not. |
|
Mr. Kennedy. Understood. |
|
Mr. Hagg. It really would be up to CMS, as the action |
|
official, to look at the information. If they wanted to come |
|
back and ask us to look at it, too, we would do that. But it |
|
would be up to CMS to try to resolve our findings and then the |
|
additional information, I guess, that the state has |
|
Mr. Kennedy. Great. And I come at this from the perspective |
|
that I agree with you wholeheartedly that program integrity is |
|
absolutely critical. |
|
And to the extent that the Commonwealth of Massachusetts |
|
OIG and CMS are able to work together to address the issue and |
|
didn't, I think it is fantastic. I think it is an isolated |
|
issue that ended up coming from a series of concurrent changes, |
|
such as the new information systems launch and, at the same |
|
time, a one-time stimulus. Hopefully, those challenges are |
|
behind us. |
|
Ms. Mitchell, if I can ask, you noted in your report that |
|
the FMAP is utilized to determine the federal share of other |
|
programs in the government as well. I was hoping you could |
|
comment on this and lay out a few of them. |
|
Ms. Mitchell. About what? |
|
Mr. Kennedy. The ways that FMAP is used for other programs. |
|
Ms. Mitchell. Sure. The regular FMAP is used to determine |
|
the federal share of a number of programs. And the ones that I |
|
am recalling right now are the Temporary Assistance for Needy |
|
Families Contingency Funds and the Foster Care Title IV-E |
|
funding. |
|
Mr. Kennedy. And so, ma'am, if our committee were to adjust |
|
FMAP funding in any way, we would also be affecting the funding |
|
for those programs as well. Is that right? |
|
Ms. Mitchell. I think it depends on how the legislation is |
|
written. If it is specific to the Medicaid program and you |
|
maintain the FMAP for the other programs, you could do that or |
|
it could apply to the other programs. |
|
Mr. Kennedy. OK. Thank you very much. And I yield back, Mr. |
|
Chairman. |
|
Mr. Pitts. The chair thanks the gentleman. I now recognize |
|
the gentleman, Mr. Ca AE1rdenas, 5 minutes for questions. |
|
Mr. Ca AE1rdenas. Thank you very much, Mr. Chairman. |
|
I thank you all for joining us today. We appreciate your |
|
knowledge and your expertise on these matters. |
|
My first question is for Mr. Hagg. One report that OIG has |
|
highlighted was a review of federal reimbursement for family |
|
planning services in California, specifically in the San Diego |
|
area. I would like to take a moment to discuss a portion of the |
|
report. |
|
In this report, over half of the improper claims were noted |
|
to be for visits that included testing for sexually transmitted |
|
infections. Is it true that after this report, CMS released |
|
guidance clarifying that STI testing is classified as family |
|
planning services for the purpose of calculating the FMAP? |
|
Mr. Hagg. I am not sure that is true. I would have to look |
|
back at that. |
|
CMS put out a letter to the state Medicaid directors in |
|
2014. I probably would need to refer back to that letter. I |
|
know it clarified some previous guidance and I think it revised |
|
some previous positions that CMS had taken. I should look back |
|
at the letter but I think that would have been, sexually |
|
transmitted infections would have been, classified as family |
|
planning-related, which would be claimed at the regular FMAP |
|
rate, not at the enhanced family planning rate. |
|
Mr. Ca AE1rdenas. OK, thank you. I appreciate that, Mr. |
|
Hagg. |
|
I also think it is also worth noting that as a result of |
|
OIG's recommendations, we have made programmatic changes to |
|
maximize program integrity moving forward, such as implementing |
|
an ICD-based reimbursement system. OIG's oversight has, indeed, |
|
provided worthwhile suggestions beyond STIs, which we are |
|
appreciative of. |
|
On the whole, I am pleased that this discrepancy in |
|
interpretations between the states and OIG has been resolved. I |
|
hope that with this administrative issue resolved, we can |
|
continue to move past this and past the simple difference of |
|
opinions and towards further actions that strengthen Medicaid |
|
for all of our beneficiaries. |
|
I have another one. My next question is for Dr. Schwartz. |
|
Again, thank you for joining us, doctor. |
|
I would like to ask you a question regarding upcoming work |
|
you noted in your testimony. In the summary sections, you noted |
|
that MACPAC is now focusing intensively on financing and design |
|
questions associated with alternatives, such as block grants, |
|
per capita caps, and capped allotments. I was somewhat alarmed |
|
that the sentence went on to describe that it would examine |
|
issues related to these alternatives, specifically baselines, |
|
growth factors, and state contributions. Were these three items |
|
only made as brief examples or does MACPAC plan to examine |
|
other effects of financing changes as well? |
|
Ms. Schwartz. Yes, they are both design issues to consider, |
|
which are those that were mentioned in my written statement as |
|
well as issues of impact. And a work plan analysis will also |
|
look at the impact on states, plans, providers, and |
|
beneficiaries. And another type of impact that we intend to |
|
look at is how changes in financing could affect other programs |
|
that rely on Medicaid to finance medical care for populations |
|
they serve, such as child welfare and special education. |
|
Mr. Ca AE1rdenas. OK, so you are cognizant of what could |
|
occur as a result of these alternative financing mechanisms and |
|
how they would affect system deliveries amongst all of our |
|
states. |
|
Ms. Schwartz. Yes, that is part of our work plan. |
|
Mr. Ca AE1rdenas. OK. One concern that has been raised is |
|
that alternatives to restructure Medicaid financing are often |
|
intended to reduce federal Medicaid expenditures. This |
|
subsequently places a larger burden on states and providers. I |
|
am concerned this could have a negative effect on access to |
|
care. Will this consideration be included in the June report? |
|
Ms. Schwartz. Yes. |
|
Mr. Ca AE1rdenas. OK. When you say yes, to what effect do |
|
you elaborate on that? Do you give examples? Do you extrapolate |
|
out on previous examples where we have done cuts in the past? |
|
Ms. Schwartz. I think our analysis will do both. We |
|
certainly have the experience from what states do now, when |
|
facing constrained spending. We can use data to help us look at |
|
the impact of different assumptions and so we can do both |
|
qualitative and quantitative analyses to look at those |
|
questions. |
|
Mr. Ca AE1rdenas. And are there potential examples where |
|
cuts have had negligible to beneficial effects on local output |
|
of services and do we have examples that you could actually |
|
point to that have had negative effects in the past? |
|
Ms. Schwartz. The states have sort of a defined tool kit in |
|
which they currently use to address issues of spending growth. |
|
They can address enrollment. They can addresses, prices, |
|
payment rate. They can address covered benefits and they can |
|
also do innovations to change the delivery of care and all of |
|
those provide good examples for helping us think about future |
|
approaches to finance. |
|
Mr. Ca AE1rdenas. Thank you so much, Mr. Chairman. |
|
Mr. Pitts. The chair thanks the gentleman. I believe that |
|
concludes questioning now. |
|
I remind members they have 10 business days to submit |
|
questions for the record. So, they should submit their |
|
questions by the close of business on Wednesday, February 24th. |
|
Good hearing. Very complicated issue. Important to educate |
|
all the members and the public. Thank you very much for your |
|
testimony. Without objection, the subcommittee is adjourned. |
|
[Whereupon, at 12:08 p.m., the subcommittee was adjourned.] |
|
[Material submitted for inclusion in the record follows:] |
|
|
|
|
|
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] |
|
|
|
|
|
[all] |
|
</pre></body></html> |
|
|